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ABSTRACT
Due to recent advances in enzyme immobilization and 
isolation in conjunction with increasing understanding of 
soluble, labile cofactor retention and recycling, it now 
appears feasible to design an extracorporeal hemoperfusion 
device incorporating an hepatic microsomal oxidase that is 
capable of duplicating at least one of the biochemical path­
ways of hepatic detoxification in man. Several designs are 
proposed, each emphasizing the various advantages of enzyme 
immobilization, membrane modification for selective isola­
tion of cofactors and reaction media, macromolecular cofactor 
analogues, and an situ enzymatic cofactor regeneration 
system.
Enzyme catalyzed oxidation rates on the order of 1.5 
yM/min/g catalyst were observed in platelet-free serum, 
ultrafiltered serum, and organic buffer. An 80% reduction 
in required cofactor concentration has been achieved through 
an situ enzymatic regeneration system. Furthermore, the 
design of a cofactor selective membrane capable of reducing 
charged NADP* fluxes by 44% is described. More ad­
vanced techniques of cofactor retention and multi-enzyme 
catalysis are discussed in a recommendations section.
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TOWARDS AN ARTIFICIAL LIVER 
CHAPTER I 
INTRODUCTION
Man as Machine
The human body, as to its natural actions, is truly 
nothing else but a Complex of Chymico-Mechanical 
Motions, depending on such Principles as are purely 
Mathematical. For whoever takes an attentive view 
of its Fabrick, he'll really meet with Shears in 
the Jaw-bones and Teeth. . . Hydraulick Tubes in 
the Veins, Arteries and other Vessels . . .  a Pair 
of Bellows in the Lungs, the Power of the Lever in 
the Muscles, Pulleys in the Corners of the Eyes, 
and so on. (1)
The above, an excerpt from the preface of Richard 
Mead's Treatise, A Mechanical Acount of Poisons, illustrates 
a fashionable analysis of man strictly in terms of the 
mechanics of Galileo and Newton. It was published in 1702.
Astonishingly, this is the dictum followed by most 
biomedical engineers today. The artificial kidney and 
artificial heart-lung, first realistically proposed in 
1948 (5) and 1954 (4), respectively, remain to this day 
the only clinically accepted artificial organ substitutes. 
Yet their operation depends strictly upon physical phenom­
ena.
With the advent of biochemistry, essentially a twenti­
eth century creation, efforts have been made to explain the 
functions of the body in terms of chemical reactions. Engi­
neers have only recently begun to grasp the initiative in 
this area (23) . The total ramifications of applied biochem­
istry (biochemical engineering) is indeed awe inspiring:
Any or all biological phenomena associated with life can in 
theory be duplicated, singly or completely, in a synthetic 
system. In an effort to avoid the theological and philo­
sophical disputes inherent in the above statement, it would 
seemingly be prudent for today's biochemical engineer to 
bite off a more chewable portion —  but where to begin, and 
how?
Before we become overly cocksure with the abilities 
of modern engineering, let us examine two of its more stel­
lar successes and compare them with nature's version.
The heart, judged as a pump, effortlessly adapts to 
varying loads with extreme reliability. Significantly, 
the heart-lung machine, which will only take over the func­
tions of the natural mechanism for a few hours, is about a 
thousand times larger than life.
The kidney may be considered a chemical engineering 
system, designed and operated with a precision that no engi­
neer would be bold enough to imitate; the artificial kidney 
is large and clumsy, and offers numerous life-threatening 
side effects because synthetic materials cannot approach
the performance of the natural organ.
In the same vein, there is a good possibility recent 
advancements in enzyme stabilization, cofactor regeneration, 
and membrane manufacture may find successful application with 
a detoxifying liver enzyme to yield an extracorporeal device 
capable of mimicking a crucial facet of hepatic biochemictry.
The literature is incomplete in many areas, particu= 
larly those concerning the specialized oxidase enzyme involved, 
This precludes the immediate synthesis of the various modules 
presented in the following chapter to construct a viable 
working model. It is therefore the purpose of this disser­
tation to clarify the remaining hurdles and to provide a data 
base from which such a device could be constructed. 
Specifically, the research goals are:
1) To show that rapid cofactor regeneration can sig­
nificantly lower the total pyridine nucleotide content of 
the reaction medium without compromising the efficiency of 
the reaction. The end result of such a goal would be to 
reduce the flux of the toxic cofactor, and significantly 
lower capital operating costs.
2) To show that NADP selective membranes are feasible. 
The objective is once again to reduce toxic cofactor dif­
fusion to the patient, without forfeiting high reaction 
rates.
3) To show that the MFMF oxidase reaction will indeed 
occur in whole blood, plasma serum, and blood dialysate.
4) To elucidate the efficacy of high molecular 
weight cofactor analogs in such a system. The primary ob­
jective is to reduce toxicity to the patient. Although 
economics are secondary, the two goals may not be mutually 
exclusive.
All the above goals have been successfully accomplished 
in the course of the research for this dissertation.
CHAPTER II
BACKGROUND
The purpose of this chapter is three-fold. Primarily, 
it provides a condensation and analysis of the diffuse, non­
specific, and often contradictory literature concerning cur­
rent modes of extracorporeal hepatic therapy, in addition to 
a host of information surrounding a subject most aptly refer­
red to as "enzyme engineering." The continuing theme returns 
to a discussion of the many possible ways in which these seem­
ingly unrelated topics may coalesce to yield a feasible extra­
corporeal hemoperfusion device capable of duplicating various 
critical pathways of hepatic detoxification.
Secondarily, the material here is intended to be food 
for thought to the reader, regardless of his background. The 
concept of duplicating biochemical pathways in a synthetic 
system is as alien to the engineer as it is to the physician. 
Lastly, this section provides a justification for what 
some may consider a rather circuitous and unnecessarily complex 
means to an end: improved survival in advanced liver disease.
We begin with an elementary discussion of liver function, 
proceed to an investigation of how the critical functions may 
be assisted, and then through a logical series of compromises, 
arrive at a unique proposal for the extracorporeal treatment of
what is presently termed irreversible liver disease.
Liver Function
Excellent engineering predominates again in the liver, 
where complex processes are carried out at low temperature 
and without any of the powerful reagents which would be 
necessary in the laboratory. The liver plays roles in blood 
storage, bacterial filtration (99% per pass), and in bile 
production for digestive purposes. In addition, the healthy 
liver is often considered the chemical processing plant for 
almost every substance absorbed and distributed by the blood. 
The blood, which has picked up various substrates through 
the lungs, skin, alimentary canal, and elsewhere, perfuses 
the liver via the hepatic portal vein. The hepatic artery, 
in turn, provides an ample supply of oxygen. Once in the 
liver, nutrients and other substances are removed from the 
blood, metabolized, possibly stored for a time, and then 
released back into the blood. This metabolism is the net 
effectof a specific sequence of chemical reactions which 
depend on the substrates (precursors) encountered, and the 
needs of the body. Because these reactions have heretofore 
been difficult or impossible to achieve in-a manner compa­
tible with a living system, a truly artificial liver exists 
today only as science fiction.
These transformations are made possible at the proper 
time and environment by enzymes. These high molecular weight 
protein molecules posses catalytic activity. They are, by
7most definitions, not living, but it is noteworthy that an 
enzyme, ribonuclease, has been synthesized "from scratch" (6) 
in the laboratory, and with it researchers have been able to 
assemble a fundamental precursor to life; RNA.
Due to the fact that many enzymes are non-specific 
with respect to substrate, yet highly specific to their ac­
tion on that substrate, a relatively small number of enzymes 
may catalyze a wide array of reactions. In the liver, for 
example, amino acids are made into proteins and other nitro­
genous compounds; glucose is converted into glycogen and 
stored, to be converted back into glucose and released when 
needed. And, drugs and other toxic substances, from which 
no useful energy or chemical products can be extracted, are 
detoxified (and in rare cases, activated) (7).
The engineering excellence of living organs, such as 
the liver, is counterpointed only by a single flaw; they 
will eventually and irreversibly cease to function. In 
1970, thirty thousand people died from cirrhosis alone (8). 
The future, with its increased industrial contamination and 
the effects of high population densities, will offer no 
respite for the liver already overtaxed by alcohol, thera­
peutic drugs, and food additives (9,15,16,17). Surprisingly, 
no effective drug therapy exists today for so-called irre­
versible liver failure (10). Hepatic failures, regardless 
of the causative disease, are complex entities whose etiolo­
gies remain essentially undefined, and treatments have yet
8to be established. Currently practiced treatments are con­
servative, general, non-specific, and of value only in tem­
porary symptomatic relief or general support (12). Indeed, 
many drugs that one might prescribe cause an increased load 
on the diseased liver (19). The prognosis of fulminant li­
ver failure is closely linked to the severity of encephalo­
pathy, with survival of those patients in grade-IV coma 
(unresponsive to verbal commands) being around 10-20% (13, 
14). Consequently, liver disease is often characterized by 
a descending spiral of liver efficiency resulting in hepatic 
coma and death (11).
One quality of the liver, however, sets it apart from 
all other organs (with the possible exception of the skin). 
Given the opportunity to recuperate, the liver is capable of 
rapid and spontaneous regeneration after disease or trauma 
(18). Rat liver, as an extreme example, when surgically 
excised to 25% of its original size, will completely regen­
erate within three days (20). Even man can survive after 
90% hepatic resection (21). Due to the essential functions 
of the liver, a no-load period in which it may regenerate 
is currently unattainable after the onset of cirrhosis (22), 
or potentially lethal intoxications (23). Clearly, clini­
cal medicine would welcome an extracorporeal device that 
could at least assist in some areas of liver function for 
a sufficient period of time to allow recovery.
Project Scope
During the protracted development period preceding the 
invention of the automobile, someone had the amazing fore­
sight to first discover the wheel. In artificial liver 
research, science is now at the point of determining which 
part is to be invented first (hopefully with equal foresight) 
For the time being, due to biomaterials limitations 
among others, a permanent hepatic device is unrealistic (24), 
and probably unnecessary. However, a reasonable objective, 
a ten-year goal, for example, would be to build a device 
using all current technology, and anything new discovered 
during its development, that would mimic at least some func­
tions of the liver —  preferably those most essential to the 
support of life —  for a period of hours or perhaps days.
By then, hopefully, the patient's liver will have recovered 
sufficiently on its own (or with drug therapy tolerated by 
the diseased liver when assisted artificially) to effect a 
complete recovery. What, then, are life-threatening liver 
deficiencies? Let us review the principal functions of the 
liver:
1) Protein synthesis and bile production can be 
considered long term goals of the liver, but not 
life-threatening in the initial phases of hepatic 
failure.
2) Glucose release is critical, yet can be
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controlled effectively with intravenous injec­
tion (25). Additionally, fresh frozen plasma 
may be administered as a source of coagulation 
factors although they have dubious effectiveness 
(25).
3) Blood storage and its resultant effect, blood 
pressure control and RBC content can also be con­
trolled by the physician.
4) Anti-bacterial functions can be assisted 
initially through drug therapy alone, but it is 
significant that massive infection is the almost 
certain cause of death in chronic liver disease
• (26).
The remaining liver function, metabolism of endogenous and 
foreign toxins, remains unassisted with current clinical 
practices (22). it is no mystery then that physicians and 
engineers alike have attacked the problem of liver detoxi­
fication head-on in the past 10 years. A review of this 
work follows.
Review of the Literature 
Artificial liver research, per se, has found only 
limited interest. Index Medicus cites one reference for 
1976 (27), four for 1975 (28-31) and three for 1974 (32-34). 
Purported clinical studies are even scarcer. Typically,
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three or four case histories are followed in patients with 
potentially terminal liver disorders. The results of a 
particular hepatic support therapy are statistically incon­
sequential not only because of the small sample size, but 
also due to the fact that the patient usually dies anyway.
If the patient has survived, it is not clear whether this 
was the result of the therapy, or in spite of the therapy. 
The techniques range from the Frankensteinian to the beastly.
Parabiosis
Eschbach has reported the use of a living partner, 
either animal or human, as a means of extracorporeal hepatic 
support (35). Typically, arterial shunts connect the hepa­
tic failure patient to the liver of the healthy parabiotic 
partner. The patient's blood is returned in a venous shunt 
from the partner's hepatic portal vein. Other modifications 
of this technique involve mutual blood transfusions in which 
intimate mixing of the partner's blood occurs between simple 
femoral venous shunts (36). Potential parabiotic partners 
in either case must be closely screened for blood antigen 
compatibility. Nevertheless, this has not prevented bold 
attempts to use humans, orangutans, and gorillas as hepatic 
support partners (37,38,39,40,41). The concept of sedated 
gorillas as bed partners underscores the desperation of 
the medical community concerning hepatic failure. Human 
benefactors, unfortunately, are hard to come by. As might 
be expected, there is considerable risk to both partners.
12
and in many hepatic diseases (i.e., serum hepatitis), rapid 
infestation of the disease is all but guaranteed in the 
healthy partner (42). Successful parabiosis has not been 
reported in the literature within the last three years.
Transplantation
Organ transplantation is, in the strictest sense,
(and indeed, as far as the body is concerned) an extracor­
poreal device. It therefore earns a mention in this review.
The longevity record of 168 days for a whole trans­
planted liver is currently held by the University of Colorado 
Medical Center in a 7 year old girl (43). The patient was
comatose intermittently during this period. In addition, 
liver support was assisted by hemodialysis and experimental 
drug therapy. In the interest of keeping the patient alive, 
controlled experimentation was not possible, and the issue 
of hepatic transplantation remains a clouded issue. The 
consensus of clinicians at this point is that hepatic trans­
plantation should be abandoned until effective immunosup­
pressive therapy is available. Even then, the demand for 
donors will far outstrip the supply, as is painfully obvious 
with kidney transplantation today. (Perkins has proposed 
an interesting hypothesis that the immunorejection of an 
organ is directly related to its biochemical complexity, 
and as such researchers should concentrate their efforts 
on those components most successfully transplanted (44).
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The liver, incidently, is far down on his list for poten­
tial tranplantation.) At any rate, the objective of whole 
liver transplantation is that of permanent hepatic replace­
ment. As stated earlier, this is neither within the scope 
of this paper nor within the ten-year goal of this project.
Liver grafting is currently enjoying the limelight in 
the medical literature (5 references in 1976) (45-49). It
is included under this heading because it, too, is proposed 
to be a long range surgical therapy. The graft, ranging 
in size from one to several cc's of liver tissue may come 
from a suitable partner or from a non-diseased portion of the 
patient's own liver. (The liver is often assumed to be homo­
genous both with regard to structure and to function.) Hep­
atic regeneration is then activated with drug therapy in the 
hope that the graft will become active (47). In isolated 
cases, the surgery alone seems to trigger hepatic regener­
ation (49). To date, permanent liver grafting between non­
identical twins has failed, and this has limited the tech­
nique to cases of isolated neoplasms where homografting 
may be effective (45).
Selective Chemical Adsorbents
Rosenbaum (50,51,52) has reported on the use of a 
resin adsorption column that somewhat selectively removes 
foreign compounds in acute, life threatening drug intoxi­
cation. Additionally, Willson (42) describes hemoperfusion 
through charged and uncharged ion exchange resins for the
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removal of choleophilic anions from dogs with biliary con­
striction. Perfusion of the resins "Dowex-1" and "XAD-2" 
removes a variety of protein bound anions from plasma.
Resin hemoperfusion, however, results in extreme hemolysis 
plus lowered platelet counts within two hours, obviating this 
technique in patients with liver failure, who already have 
a bleeding diathesis and often have profound thrombocytop­
enia (24). Weston has attempted resin perfusion with plasma 
obtained from an Aminco continuous cell-separator in dogs, 
but losses of blood platelets was not demonstrably lower 
than in whole blood perfusion (24,25,82).
The adsorbent properties of activated carbon have 
been known for many years. Typically, it will remove from 
blood water soluble compounds such as aminoacids and crea­
tinine (55). Unfortunately, most blood toxins are lipid 
soluble. In addition, hemolysis remains troublesome, coupled 
with the catastrophic effects of small carbon particle emboli. 
Two methods have greatly increased the biocompatibility of 
activated carbon; both involve containment within polymer 
fibers. Chang has successfully microencapsulated both char­
coal and ion exchange resins in collodion and nylon mem­
branes (53). This will be covered in more detail later.
Bruck has achieved considerable success in coating indi­
vidual charcoal particles with a variety of polymers, in­
cluding hydrogels (54). In both instances, a penalty must 
be paid due to the exclusivity and rate-limiting character­
istics of such polymer films.
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Dialysis
Direct hemodialysis is probably still the most clini­
cally acceptable method of extracorporeal hepatic support 
(56,57). Peritoneal dialysis has found less acceptance, 
but the principles involved and net effect are much the 
same. Potential toxins are removed from the blood due to a 
concentration gradient across a synthetic membrane or the 
peritoneum. Lack of selectivity has been offset by the 
expertise gleaned from artificial kidney research. Recent 
evidence, however, indicates that neither peritoneal dialy^ 
sisn or hemodialysis seem to be effective at improving the 
level of consciousness in level IV coma (25,58,59). The 
pathogenesis of the resulting encephalopathy is not clear, 
although one possibility is that the healthy liver synthe­
sizes unknown factors necessary for brain function. This 
hypothesis is supported by data collected from crossed- 
hemodialysis experiments in which CCl^ induced acute hepatic 
coma in pigs was improved by dialysis against the hemodialy- 
sate of a healthy pig, whereas hemodialysis against a syn­
thetic medium was ineffective (60). Zieve, et al., (61,62), 
support the more likely conclusion that an accumulation of 
some unknown toxin is a more likely causation of the ence­
phalopathy. Their work suggests the synergism between 
ammonia, short chain fatty acids, and mercaptans. Others 
point to changes in the metabolism of plasma-amino acids 
which may lead to the accumulation of false neurotransmitters
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in the brain (59). The ineffectiveness of dialysis indi­
cates that low molecular weight water soluble toxins such 
as ammonia are not totally responsible. Other toxins may 
either be lipid soluble and bound to plasma proteins, high 
molecular weight compounds, or selectively charged. Hemo­
dialysis with different membrane characteristics is always 
a continuing subject of research.
Microcells
Chang has investigated a series of biomedical applica­
tions for his "artificial cells" since their initial pre­
paration in his laboratory in 1956 (71). Chang has repeat­
edly suggested their use in an artificial kidney and an 
artificial liver (53,63-67). Their preparation is typically 
the result of condensation polymerization occurring, at the 
interface of two dispersed immiscible fluids or through 
the physical phenomenon of coacervation. He has successfully 
encapsulated any number of exchange resins and activated 
charcoal in addition to their potential in straight dialysis 
(68,69). At first, enzyme microencapsulation proved unfea­
sible due to the harsh preparatory conditions. In recent 
years, however, many enzymes have been successfully immo­
bilized by this technique while retaining activity, further­
ing the potential utility of the invention for enzyme re­
placement therapy, artificial blood cells, and tumor therapy. 
In a recent paper (70), Chang has reported the microencap­
sulation of an oxido-reductase enzyme system which cycles
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automatically, regenerating the enzymes and the coenzymes
involved while consuming necessary substrates which pass
through the membrane. This method offers great potential
in duplicating complex enzyme systems, much like those that
occur in the liver.
The artificial cells may be administered by direct
i.v. injection, peritoneal injection, oral consumption, or
perfused in an extracorporeal device. The latter case has
been explored most thoroughly in the literature. Techniques
for modification and optimization of the membrane properties
are abundant. There nevertheless exist upper bounds for
molar fluxes and molecular weight cutoffs, but the high sur-
2
face area available (2,500 cm /ml) (67) often offsets their 
limitations.
Extracorporeal Biological Devices 
The methods discussed up to this point cannot be ex­
pected to replace or substitute for the liver's complex 
enzymatic functions, many of which still remain unknown. 
Because of the lack of understanding of the total scope of 
hepatic functions, utilization of biological tissue has been 
attempted by various investigators. The biological systems 
employed include healthy donor blood (72-75,78)> as a trans­
mitter of liver functions, and liver tissue itself, in 
various forms of preparation (10^76-81) . These techniques 
have largely met with failure due to preparation and pro­
curement complexities, storage and preservation, and
18
immunology. Various methods of liver cell culturing and 
preservation exist. Essentially, they fall into two cate­
gories; (1) blood perfusion of large surface areas of healthy 
liver; and (2) blood perfusion over cultured colonies of 
hepatomas (85-87). (Normal liver tissue will not replicate 
successfully vitro) (83,178)
In the first case, rapid degradation of catalytic 
properties due to the presence of proteolytic enzymes in 
the tissue is observed regardless of the method of prepara­
tion. This is a naturally occurring process in all non­
living tissue, which necessitates the excision, preparation, 
and use of any hepatic tissue within 15-30 minutes. The 
elevated temperatures (37-38 C) at which all of these analy­
ses have been conducted undoubtedly accelerate the rate of 
isozymic decay. This may be unnecessary, Sofer has shown 
that the optimum temperature for at least one hepatic oxi­
dase enzyme is well below physiological temperature (84). 
Perhaps increased half lives could be observed in these 
hepatic support devices at lower operating temperatures 
without sacrificing catalytic activity. This has not been 
shown in the literature.
The second case sidesteps the decay problem by main­
taining a steady-state vitro cell culture which is then 
directly (or indirectly, across a membrane) perfused with 
the patient's blood. Yet the concept of continuously expos­
ing one's blood to a thriving, malignant cell culture may
19
offer a cure worse than the disease. The question of in­
complete or abnormal liver function in the hepatoma has also 
been raised (85).
Critical Analysis of the Current Literature in Review
1) No universally acceptable technique exists for 
extrahepatic support.
2) One method makes an attempt to duplicate actual 
hepatic biochemical pathways, with little positive effect.
3) One reference strives to remove protein-bound 
toxins (pesticides, drugs, and potentially numerous unknown 
endotoxins).
4) All other techniques stress removal of free, low 
molecular weight toxins, which is not the primary function 
of a normal liver. One primary mode of detoxification in 
the liver is to convert lipophilic, protein-bound compounds 
to hydrophilic products which can then be excreted by the 
kidneys. Removal of critical endotoxins remains unexplored.
5) Toxicity, hemolysis, immunological complications, 
and other side effects of varying degree in each case com­
promise any net detoxification of which the device may be 
capable.
A Proposal
Attempts to duplicate isolated examples of synthetic 
liver function ^  vitro with purified liver enzymes have 
been infrequent (25,88,89,90). Likewise, reproduction of
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detoxifying liver metabolism has been thwarted by the un­
availability of the necessary hepatic enzymes.
If one or more of these enzymes could be incorporated 
in an extracorporeal shunt reactor, it would provide a test 
bed on which to run successive tests evaluating the reactor's 
effect on various substrates. It would at the least be a 
major step toward temporary hepatic support, and could con­
ceivably see clinical use in detoxification of specific sub­
strates transformed by the particular enzyme.
The reactions of concern here are catalyzed by a class 
of "mixed function oxidases"; enzyme complexes that require 
oxygen and a hydrogen-carrying coenzyme, are nonspecific, 
and which oxidize a substrate as shown in Figure 1. They 
are not only critical as an end in themselves, but also as 
intermediate steps in overall liver function; for example, 
after the crucial oxidation step, conjugation may occur.
With few exceptions, either the oxidized or the oxidized/ 
conjugated compound is devoid of substantial biological 
activity.
Exceptions to this rule have surfaced in recent years, 
no doubt due to the cataclysmic changes occurring in the 
environment. Man's biochemistry has been attacked by a 
great variety of new drugs, agricultural chemicals and pol­
lutants against which the body has no natural defensive 
mechanism. Up to a point, the liver can deal with toxic 
substances using its available enzymes in its customary
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Figure 1. (7) Typical Oxidation Reactions Encountered in 
the Liver. Transformations such as these are the primary 
pathways of detoxification, yet their duplication in the 
laboratory, or expecially in an artificial organ, is diffi­
cult without the specific enzymes required in each case.
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way to promote chemical changes which may make the unwanted 
materials less dangerous or more soluble and therefore more 
easily disposed of in the urine. For example, the endotoxin 
ammonia (formed in the breakdown of proteins and highly toxic) 
is converted to urea, which is relatively harmless, and 
easily excreted. But when the chemical defenses of the li­
ver are challenged by a man-made chemical, the outcome may 
or may not prove successful. Barbiturates are converted to 
less toxic chemicals, but tetraethyl lead and the insecti­
cide parathion, which are non-toxic in themselves, are con­
verted to highly poisonous compounds by enzyme action in 
the liver. This activation may be circumvented in those 
particular cases where these known intoxications exist by 
the prudent selection of hepatic enzymes in the shunt re­
actor.
A rare opportunity was offered this laboratory when 
Professor D. M. Ziegler of the University of Texas' Clayton 
Foundation agreed to supply large quantities of a mixed 
function microsomal flavoprotein (MFMF) he exclusively iso­
lated from hogs (91,92,93). Until 1975, it was the only 
example of a purified hepatic detoxifying enzyme. These drug 
metabolizing enzymes are present predominantly on the smooth 
surface filaments of hepatocyte endoplasmic reticulum. The 
metabolic role of the oxidase is yet to be elucidated, but 
based upon its extremely high concentrations in liver tis­
sue (up to 20% of total E.R. protein), it is believed to be
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of significance in liver detoxification.
As a result, it is proposed that this enzyme, in con­
junction with its allied coenzymes, is capable of relatively 
long-term activity in an extracorporeal device with a mini­
mum of harmful side effects. Only in such a "clean" system 
can the net effect of a particular therapy be followed in 
controlled experimentation on a wide data base. This paper 
is the result of a series of broad spectrum investigations 
that provide a basis on which such a device could be con­
structed.
Characterization of the Enzyme 
The MFMF enzyme complex, from here on to be referred 
to as simply an "MFMF oxidase" is thought to be a relatively 
high molecular weight (-400,000) oligomeric complex contain­
ing multiple flavin functional groups tightly bound to allo- 
steric sites on the enzyme which give it a characteristic 
yellow color. The FAD released on hydrolysis is a fortui­
tous method of determining enzyme concentrations spectro- 
photometrically in instances where protein analyses would 
be difficult or impossible. There are perhaps six monomers 
in the oligomer.
This particular oxidase is highly specific to second­
ary and tertiary amine containing substrates. A number of 
potential toxins in thiÿ category are: chlorpromazine,
N-methylparaaminoazobenzene, ethylmorphine, brompheniramine, 
prochlorperazine, and l-methyl-l-phenylhydrazine.
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It catalyzes the conversion of secondary and tertiary amines
to N-oxides with the consumption of one mole of reduced
nicotinamide adenine dinucleotide phosphate (NADPH), and one
mole of oxygen per mole of oxide formed. The reactions
involve an external electron donating system as follows:
0
Î
X -N -R j- + NADPH + H+ + 0^ > + NADP+ + H^O
^2 *2
OH
X -N -R , + NADPH + H+ + 0^------------ > X -N -R , + NADP+ + H_02
Typically, R^ and Rg are methyl or ethyl groups. They 
may, however, as in the case of prochlorperazine (94) , be 
part of a ring system. A lipophilic alkyl or aryl group 
free from polar groups on the alpha carbon is indicated by 
"X". A functional group more polar than a hydroxyl within 
a two atom radius of the nitrogen prevents oxidation. Ter­
tiary amines are converted to N-oxides, secondary amines 
to N-hydroxy amines, and thioureylenes are S-oxidized (84, 
93,95).
Additionally, there is no indication that this oxi­
dase resembles the recently isolated cytochrome' P-450 sys­
tem which acts as the terminal oxidase in a microsomal 
electron transport chain (164-167). Cytochrome P-450 is ac­
tivated by phenobarbitol and inhibited by CO. The MFMF 
oxidase exhibits none of these properties (84,95).
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The reaction is essentially irreversible. Octylamine 
is one of the few activators known. This enzyme may com­
pose as much as 2 0% of all endoplasmic reticulum protein.
All known enzyme reactions are controlled, turned on and off 
at the proper time, if you will, by a complex system of checks 
and balances such as feedback inhibition. The search for 
the control mechanism of this enzyme continues. All reac­
tions with this enzyme will essentially go to 100% comple­
tion if given time.
Activation of the oxidase is believed to follow a dis­
tinct sequence: 1) molecular oxygen binds at the single
active site; 2) like all oxido-reductases, a suitable soluble 
cofactor*, in this case, NADPH, (or NADH, with far less 
efficiency) binds at a specific allosteric site; 3) the sub­
strate binds at the active site, and catalysis occurs; 4) 
the product and oxidized cofactor are released.
* The term "cofactor" is, in the strictest sense, a misnomer. 
Cofactor implies a small, non-protein molecule necessary 
for the enzyme's catalytic activity, but which is not con­
sumed in the reaction. Typically, transition metal ions 
fill this role. The hydrogen carrying "cofactor" in this 
context ^  consumed in the reaction, and is therefore more 
correctly defined as a cosubstrate. Indeed, in kinetic 
analyses, this entity must be treated as one substrate in 
a multiple substrate system. As a concession to avoid 
ambiguity with the current literature, which inexplicably 
refuses to acknowledge this fact, the terms cofactor, co­
enzyme, and cosubstrate will be used interchangeably to 
refer in context to the compounds NAD, NDAP, and FAD.
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The cofactor necessary for this enzyme adds a signifi­
cant complexity to its application:
1) It is quite expensive, yet must be avail­
able in relatively large quantities. On a 
molar basis, one must start out with at least 
as much cofactor as the amount of product de­
sired.
2) It plays an essential role in the reaction 
mechanism, yet it cannot be duplicated by any 
other compound.
3) To perform its function, it must be bound 
to the enzyme at the proper time. At all other 
times it must be in free solution with the en­
zyme. This further complicates the issue of 
separating the products from the reaction medi­
um.
The concept of irretrievably consuming a very expensive com­
pound (NADPH, at $200,000/mole) (96) on a one-to-one molar
basis with the product has provided a considerable incen­
tive to develop a compatible system of regeneration so that 
the cofactor can be re-used.
The regeneration, in actuality a simple reduction of 
the oxidized NADP+ to NADPH, may be achieved through treat­
ment with dithionite (97,98). This is an effective method 
of preparation of NADPH from the less expensive NADP+ in 
the laboratory, but the process is much too harsh for in
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situ regeneration within an enzyme medium. Electrolytic 
reduction has also been reported, but with relatively low 
conversion and some decomposition of the parent compound 
(163). This lack of specificity and accompanying degrada­
tion becomes critical in a process incorporating a large 
number of turnovers. As Chambers (99) has pointed out, a 
regeneration process with 99% specificity would lose 63% 
of the starting cofactor after 100 regenerations.
An alternative is to reduce the cofactor enzymatically. 
Although the emphasis in the MFMF oxidase discussion has fo­
cused on an oxidation process in which NADPH is consumed, 
there is no reason to doubt the existence of an enzymatic 
reaction with the obligatory production of NADPH from NADP^. 
Indeed, such is the case. Alcohol dehydrogenase, isocitrate 
dehydrogenase, and glucose-6-phosphate dehydrogenase are 
three examples of relatively inexpensive, commercially avail­
able, stable enzymes which possess this quality. Further­
more, all have shown the capability of regenerating NADP+, 
with the consumption of an appropriate hydrogen donor, 
simultaneously with the MFMF oxidase reaction (84,100,101).
The key issue in the proposal of this thesis is to 
explore the varied ways in which this enzyme-cofactor com­
plex, and eventually others resembling it, may be applied 
as a temporary hepatic support. Various hypothetical and 
largely speculative methods follow.
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Methods of Application
Direct Oxidase Injection 
The positive aspect of direct intravenous injection 
is its obvious simplicity. In addition, i.v. injection is 
normally considered a non-traumatic procedure offering mini­
mal discomfort for the patient and a conventional mode of 
application with which most physicians are comfortable.
The negative aspects far outweigh these advantages.
The oxidasewould quickly be identified as foreign protein 
in the blood and could easily lead to massive allergic re­
actions and anaphilactic shock. This has been proven time 
and again with other enzymes injected directly (102,103). 
Clinically effective levels of L-asparaginase, for instance, 
which has potential as an anti-cancer agent, cause a wide 
range of toxic effects on several organs including the liver, 
pancreas, kidney, and brain (104-106) . The same has been 
shown for direct infusion of a-galactosidase in the treat­
ment of Fabry's disease, regardless of the degree of purity 
of the extract (107). Furthermore, the MFMF oxidase has 
been shown to havea half life in buffer at 37 C of less 
than 5 minutes. The catabolic effects of the blood would 
further reduce its utility. Cost and availability of the 
oxidase must also be accounted for, even ignoring the re­
cently developed tools of enzyme purification with affinity 
chromatography and advanced tissue culture methods. NADPH 
must also be present, yet its concentration in blood plasma
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is not known. Within the red blood cell, concentrations of 
30 uM have been reported (108,109). This may be adequate 
for some degree of conversion. It is unlikely, though, that 
such quantities will be found in the plasma in contact with 
the injected oxidase, because the free cofactor is apparently 
quickly metabolized through phagocytotic attack (110). In­
jection of the purified cofactor with the oxidase poses even 
more serious side effects. NAD and NADP, like other related 
adenosinic substances, possess potent vasodepressor action 
in dosages as low at 50 ug/kg body weight, depending on the 
experimental animal (111,112). The extent of its effect in 
man has not been reported. The response, however, is short 
lived —  usually on the order of 2-3 minutes —  which stresses 
its swift and thorough metabolic anihilation. Atropine sul­
fate, when injected intramuscularly, blocks the hypotensive 
effects of NAD and NADP. Based upon the degree of vaso­
depressor antagonism of atropine against these cofactors, 
it has been determined that 50 ug/kg of NADP or NAD is ap­
proximately equivalent to 1.0 yg/kg of acetylcholine (112). 
Additionally, increased levels of corticosteroids have been 
reported with NAD/NADP injection, yet this can be construed 
as a desirable side effect, supplementing the corticosteroid 
therapy frequently prescribed in hepatic disease (111).
Immobilized Enzyme in Direct Contact With Blood
Since the initial observations by Kidd (113) on the 
antitumor activity of guinea pig serum and the evidence
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presented by Broome (114) that the active factor was L- 
asparginase, there has been a great deal of interest in this 
enzyme. As always, side effects were present when admini­
stered in large dosages, and supplies of the enzyme were 
small (104-106). As a result, a great deal of work has been 
done in the interest of immobilizing this enzyme to an 
insoluble support, while retaining catalytic activity.
Immobilization of enzymes for various purposes is well 
documented in the literature (115). In the context of this 
paper, immobilization is construed to mean the attachment, 
via an appropriate covalent linkage, of some portion of the 
enzyme to an insoluble support. The advantages are manyfold:
1) the enzyme can be retrieved for repeated use; 2) it can 
be isolated in a hemoperfusion device, greatly reducing side 
effects; and 3) often the stability of the enzyme is increased. 
The use of L-asparginase as a cancer cure has waned in re­
cent years, but the knowledge gained during its utilization 
in extracorporeal devices can readily be applied to other 
enzymes, including the oxidase of this study.
MFMF oxidase has been immobilized by various researchers 
in this laboratory and at the University of Texas to nylon, 
porous glass, sepharose, alumina, and stainless steel (84, 
100,101,116). The enzyme retains 50-80% of its activity in 
free solution, but the stability on glass beads is markedly 
increased (84).
Why this phenomenon occurs is not clearly understood.
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It is certainly the most striking example in the literature. 
Two hypotheses have been postulated. The first accounts for 
the fact that the oxidase in the liver is an immobilized 
enzyme in the sense that it is tightly bound to the wall of 
the smooth endoplasmic reticulum, and as such, in a teleo- 
logical sense, is "happier" to be immobilized once again to 
a synthetic matrix. In a mechanistic sense, the enzyme may 
be in a strained, yet more stable configuration when immo­
bilized. This is unlikely both from an entropy/free energy 
consideration and from the fact that the attachment sites 
on the enzyme are most likely not the same in the natural 
environment as they are in the synthetic. The second hypo­
thesis posited is that despite the efforts of Ziegler and 
coworkers, the oxidase preparations are inherently impure, 
containing many isozymes prevalent in the liver in addition 
to the oxidase. Upon immobilization, a somewhat non-selective 
process which affects all enzymes to some degree, the degra- 
dative isozymes that may be attacking the oxidase in free 
solution are themselves isolated. This view is supported 
by recent data on ultrapure samples of the enzyme which have 
stabilities in solution approaching that of the immobilized 
enzyme (117). The latter analysis seems the more plausible, 
but the argument is largely academic at this point. The 
fact remains that MFMF oxidase immobilization may offer 
rewards too large to ignore, including the potential for 
using relatively impure hepatic extracts —  microsomes, 
possibly.
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The stabilized enzyme has been studied in various types 
of reactors, and is currently being used to synthesize drug 
metabolites which are difficult or impossible to synthesize 
by standard organic techniques (100,101). It is not known 
what its specific properties are in direct contact with 
whole blood.
Figure 2 illustrates a hypothetical shunt containing 
the immobilized oxidase. As illustrated, the enzyme is 
attached to polymethylmethacrylate plates in a physical 
arrangement similar to one proposed by Hyden in an L-aspara- 
ginase shunt (118). Other researchers (119-124) have uti­
lized similar devices for enzyme therapy with the respective 
enzymes attached to dacron, sepharose beads, porous glass 
beads, and glass plates. By the same token, the design in 
Figure 2 could incorporate a fixed-bed, packed tower, fluid- 
ized bed, or tubular reactor. In sharp contrast to all pre­
vious enzyme replacement therapies, the immobilized oxidase 
nevertheless requires the presence of the NADPH cofactor.
The immobilization of NADP has also been reviewed 
(125-128), but when isolated to an insoluble matrix it loses 
much of its activity to enzymes in free solution, and all 
activity is.lost when both the enzyme and cofactor are 
immobilized. This fact will return time and again when 
dealing with labile cofactor dependent enzymes: at least
one moiety (either the enzyme or the cofactor) must be in 
free solution. All efforts to date with the oxidase have
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Figure 2. Simple Hemoperfusion Shunt. This is 
a modification of a design first proposed by 
Hyden for L-asparaginase therapy. A cofactor in­
jection system has been included to meet the re­
quirements of the MFMF oxidase, and a DEAE cellu­
lose scrubber is included as an option, in the 
event the rate at which cofactor is supplied to 
the reactor exceeds the body's toxic limitations. 
This design has the bovious limitations described 
on page 34.
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stressed the immobilization of the enzyme due to its in­
creased stability, and potential cost and toxicity and reduc­
tions as opposed to cofactor immobilization.
Mosbach, in a recent paper (129) , has refuted such 
statements by demonstrating the catalytic activity of a 
simple oxido-reductase with no requirement for soluble co­
factor. Basically, the technique he describes initially 
saturates the enzyme at all allosteric sites with the co­
factor (NADH). The activated complex is then entrapped and 
covalently bound to a sepharose matrix. Due to the nature 
of the enzyme involved (alcohol dehydrogenase), the entrapped 
cofactor can alternately be oxidized and reduced, depending 
on the substrates encountered. Since the oxidase in this 
study does not have the bipartisan abilities of alcohol 
dehydrogenase, the entrapped cofactor would rapidly become 
depleted. Nevertheless, the possibility of regenerating 
the free cofactor in situ is not out of the question, as has 
been discussed earlier. A remaining drawback to Mosbach*s 
novel system is that his substrates and metabolites are neces­
sarily low molecular weight compounds that diffuse easily 
through the interstices of enzyme and sepharose. As was 
pointed out earlier, the real value of external enzymatic 
hepatic support lies in the metabolism of non-d ialyzable 
higher molecular weight toxins.
Even faced with the eventuality of injecting soluble 
cofactor into the blood, one is not totally without recourse.
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Pastors has developed a diethylaminoethyl (DEAE) cellulose 
chromatography column for the selective adsorption of reduced 
and oxidized pyridine nucleotides (130). Careful elution with 
a linear salt gradient resolves sharp peaks for each moiety. 
Ignoring its application as a laboratory separation tech­
nique, the essential issue is that the column is capable of 
removing nearly all pyridine nucleotides from a complex 
fluid in a single pass. Figure 2 illustrates how such a 
scrubber may be utilized downstream of the reactor. If 
desired, the column may be removed periodically, the cofactor 
eluted, regenerated by any convenient means, and re-injected 
upstream from the reactor. A number of critical questions 
remain unanswered regarding such a system. DEAE cellulose 
is known to be a powerful adsorbent for various blood pro­
teins and salts. What effect would this have on the patient 
and on the performance of the scrubber? How quickly would 
the column become saturated? Could the spent cofactor be 
economically eluted? Would hemolysis be as serious a re­
striction with the DEAE cellulose column as it is with the 
various exchange resins being evaluated elsewhere? Many of 
these questions can be obviated, or at least de-emphasized, 
by simplifying the fluid being dealt with in the reactor 
and scrubber. There appear to be numerous advantages to 
such an approach, which will be discussed in the following 
section.
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Enzyme Isolation Via Semi-Permeable Membrane Barrier 
Figure 3 illustrates a generalized flow diagram that 
incorporates a membrane between the whole blood of the pa­
tient, and a dialysate side consisting mainly of bile salts, 
and small lipo proteins (<5000 M.W.). By selecting the per­
meability of the membrane, potential substrate molecules, as 
well as other small molecules are made to pass through the 
membrane due to the concentration gradient, while the pro­
tein and whole cell fraction is retained. This dialyzate 
solution then flows through an extracorporeal reactor con­
taining the immobilized oxidase, where the substrate is 
converted into the corresponding metabolic oxide. This 
solution is then passed across a second* membrane, permit­
ting re-equilibration with the blood, allowing the return 
of the small molecules previously removed and the net re­
placement of the toxic amine with its metabolic oxide. Thus, 
the net result is simply the selective metabolism of speci­
fic toxins.
Oreleja (131) has constructed an NADP+ regeneration 
reactor using various types of immobilized oxidoreductases. 
Its use is also illustrated in Figure 3. The refinements
* The system as drawn employs two separate membranes. This 
feature is strictly for the purpose of facilitating the 
reader's visualization of the process; it offers no physi­
cal advantage. In truth, a single membrane compartment 
performs the same function due to the same concentration 
gradients.
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Figure 3. Enzyme Isolation via Semipermeable 
Membrane Barrier. In such a system, potential 
substrates and metabolites are forced back and 
forth across the membrane by concentration gra­
dients maintained by the oxidase. The advantages 
to this technique are increased enzyme stability, 
fewer undesirable side effects to the patient.
The optional modules; reactor stream oxygenator, 
cofactor regeneration reactor, and DEAE trap may 
be included if desired. The major added dis ad­
vantage is an increase in mass transfer resis­
tance .
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of this system over the previous use of soluble oxidoreduc- 
tases for situ regeneration allows a much cleaner, simpli­
fied reaction medium, and provides for strategic placement 
of the regeneration step in the MFMF oxidase reactor loop. 
Most significantly, it can maintain an artificially high con­
centration of NADPH necessary for high oxidase rates, yet 
the total cofactor concentration (both NADP+ and NADPH), can 
be maintained at low catalytic levels. The latter benefit 
of situ cofactor regeneration has not been mentioned in 
the literature.
Chambers has reported on a system similar to that de­
picted in Figure 3 (but without a cofactor intensive enzyme 
and its allied components) utilizing a soluble enzyme iso­
lated by a cellulose hollow fiber dialyzer for the extra- 
corporeal treatment of Fabry's disease (132). The use of 
hollow fiber dialyzer enzyme reactors for vitro studies 
is also well documented (133).
Indeed, membranes are often used to immobilize an 
enzyme in free solution. Kinetic studies have been per­
formed on various soluble enzymes entrapped within the 
fibers of a dialyzer which is then immersed in the solution 
containing the substrate. After a period of time, the 
enzyme will have converted the substrate to product, with­
out contaminating the reaction medium with enzyme. Such 
a system lends itself to very stable catalysts which are 
not advantageously immobilized by covalent attachment to an 
insoluble matrix.
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Microencapsulation by the methods of Chang is a novel 
method for achieving the same net effect. As mentioned 
earlier, Chang has suggested their use in an artificial li­
ver and kidney, but due to the inavailability of a suitable 
enzyme, has been unable to produce a system capable of hepa­
tic detoxification. Of interest in this study, however, are 
the numerous advances Chang has made with other enzyme sys­
tems. The enzymes catalase, asparginase, and urease have 
been stabilized to a degree without insolubilization by 
microencapsulation with a concentrated protein solution 
(134). This has been particularly effective with relatively 
crude enzyme preparations, yet half lives are seldom in­
creased by more than 50% with this method. Recycling of 
cofactors, an issue critical to the application of the MFMF 
oxidase in microcapsules, has also been demonstrated (70). 
Although work is still progressing in this area, Chang and 
coworkers have been unsuccessful at developing microcell 
membranes with the same high molecular weight cutoffs pos­
sible with sheet and hollow fiber membranes. This may be 
the crucial factor if a microcell artificial liver were to 
be developed.
Chang's concepts have been extended recently in a paper 
by Updike (135) in which the author described the entrap­
ment of L-asparaginase in bonafide red blood cells. As a 
strategy to avoid serious allergic reactions, the process 
requires gently lysing the RBC's in a hypotonic solution
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containing the asparaginase, and then allowing the reseal­
ing of the autologous cells before injection. The possibi­
lities are intriguing, especially when one considers that 
NADP occurs naturally in catalytic quantities in the RBC, 
but probably not in serum.
In any event, isolation of large blood groups from 
the reaction medium has numerous advantages.
1) Enzyme half life is demonstrably greater, 
presumably because isozymic and whole cell 
attack are obviated by excluding the large 
proteins and cells.
2) No foreign protein enters the patient's 
blood, reducing allergic reactions.
3) Cell and protein agglomeration on the cata­
lyst surface are eliminated, hence maintaining
the highest possible reaction rates.
The major drawback is simply the reduced overall reaction 
rate created by the diffusional limitations of the membrane. 
Yet, this has been shown to be not as significant as one
might suppose when dealing with enzymes insolubilized on
porous glass beads, the most successful support used today. 
Closset (136) has demonstrated in a mathematical model, and 
shown experimentally that the diffusional resistances at 
the membrane and at the glass bead may be of a comparable 
order of magnitude. Sofer (84) has shown in a non-membrane 
system that diffusional resistances at the bead are limit-
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ing for the oxidase enzyme.
An issue that may be raised at this point deals with 
the state in which most foreign, lipophilic toxins exist 
in the plasma. They are primarily attached to large pro­
teins and globulins. The binding equilibrium lies far in 
the favor of bound toxins. Chlorpromazine, for, example, 
exists as a protein-bound complex with only 3% remaining in 
free solution (137). Membrane exclusion of such proteins 
also excludes the greatest percentage of toxin from the 
enzyme. This would seemingly be a mark against a membrane 
system, and a plus for the direct contact scheme of the pre­
vious section. This is not necessarily so. Evidence accu­
mulated thus far indicates that the oxidase, whether in 
free solution, or insolubilized on glass, will be incapa­
ble of catalysis on a substrate bound.to a large protein.
It is possible that lipophilic toxins may be solubilized 
with bile salts, in which case the oxidase may be active.
This facet has not been investigated. Nevertheless, it 
appears that the total catalytic processes of the detoxi­
fying enzymes occur only on that portion in free solution —  
3% in the illustrative example of chlorpromazine. As this 
soluble fraction is consumed in the oxidation reaction, the 
equilibrium will continue to shift until all of the toxin 
has been metabolized. This is time consuming, but it is 
the path followed by a normal liver, and it does not appear 
that it can be improved upon if hepatic enzymes are the means
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to the end. By this logic then, the artificial dialysis 
membrane compromises the potential efficiency of detoxifi­
cation no more than the cell wall of an hepatocyte. In fact, 
one can most easily visualize the system of Figure 3 as a 
giant specialized liver cell.
Another valid concern is frequently raised concerning 
the wisdom of including any enzyme in a hemodialytic detoxi­
fication system. Assuming that the sole purpose of an 
extrahepatic support device is to remove toxins, then enzyme 
catalysis in combination with hemodialysis may indeed be 
redundant. After all, once the toxin is removed, why return 
it to the patient in a less toxic form? One can, however, 
view extrahepatic support as an enzyme replacement therapy.
In this analysis, the enzyme becomes the primary necessity, 
and dialysis merely a necessary element. Also, bear in 
mind that detoxification has been selected for study here 
simply because it offers the best opportunity for a reason­
ably short-term evaluation of the project —  the 10-year 
goal having been stated earlier. This, of course, is a 
faltering first step in duplicating total liver function.
Yet if this step is to have any validity in the future, we 
must begin now by duplicating biochemical pathways and not 
short-cutting to what may appear to be the more accessible 
goals of extractive detoxification. If as Fischer (59) 
believes, the normal liver synthesizes essential neurotrans­
mitters, and lack of these compounds spawns the neuropathy 
of hepatic coma, then straight hemodialysis will never be
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an effective therapy for reversal of level IV coma. This 
has been proven clinically (58). The beauty of an enzyme 
support system is that specific knowledge of the unknown 
neurotransmitters involved is unnecessary, if the extra­
hepatic device is capable of their synthesis. It is not 
known what role the oxidase of this study may play in such 
an eventuality.
More immediate advantages to enzyme catalysis in hemo- 
perfusion devices may also be postulated. Currently, arti­
ficial kidney machines which may be used in liver detoxifi­
cation are about the size of a washing machine, expensive, 
require at least four units of blood for priming and large 
volumes (200-300 Z) of sterile dialysate to maintain the 
necessary concentration gradients. Comparatively, a urease 
enzyme reactor coupled with a hemoperfusion device incor­
porating the same membrane area of the artificial kidney 
has been constructed within the volume of a soft drink can 
(138-140). Large volumes of dialysate are unnecessary be­
cause the concentration gradient is maintained by the enzy­
matic consumption of the substrate (urea). Furthermore, 
essential metabolites that may exist only in ppm concentra­
tions in the blood would not be lost in a large dialysate 
volume. It is even plausible, depending on the compound(s) 
to be dialyzed and the rates of the enzyme system chosen, 
that higher dialysis rates could be achieved than with 
routine hemodilysis. This is especially true if the enzyme
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is immobilized to the dialysate side of the membrane wall. 
Gregor (141) has collected some data to support this.
A third significant issue that has been glossed over 
until now is the recurring cofactor dilemma : it diffuses 
easily through most dialysis membranes. Chambers (142-144) 
has sidestepped this problem in an experimental reactor for 
converting ethanol to acetaldehyde by selecting a commer­
cially available hollow fiber membrane with a particularly 
"tight" M.W. cutoff of 200. The substrates with which he 
dealt easily passed through, while the cofactor (approximate 
molecular weight of 800) was retained. Such a system may 
be adequate for treatment of some toxins in an hepatic sup­
port device. At this time, however, it is not known what 
other endotoxins may be responsible for the encephalopathy 
evident in hepatic coma, the one area that has not responded 
to any type of therapy to date. If these endotoxins are .. 
larger than the cofactor, a non-specific membrane would 
exclude them from the reaction medium, and hence from de­
toxification. It is felt, however, that some degree of 
optimization may be achieved between membrane cutoff and an 
acceptable cofactor flux into the blood. If such is the - 
case, then an extrahepatic support device could be designed 
with a much wider potential for success in dealing with the 
unknown larger toxins.
Furthermore, a DEAE cellulose scrubber could be uti­
lized in the blood return line in a manner analogous to
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that described in the previous section. This adds the po­
tential of further increasing the membrane cutoff, if de­
sired, and/or increasing the concentration of cofactors 
in the reactor loop.
High Molecular Weight Cofactor Analogs. Several lab­
oratories have taken a differing approach to cofactor re­
tention within a membrane reactor: the synthesis of a
soluble, macromolecular, enzymatically active cofactor.
Limited success has been obtained with the pyridine 
nucleotides. Wykes (145) coupled succinyl-NAD to polyethyl- 
eneimine (PEI), molecular weight 40 to 60,000. The result­
ing NAD-PEI complex contained 19-34 moles of NAD per gram 
of PEI. Of this, 45% was enzymatically reducible with alco­
hol dehydrogenase. Weibel (146) coupled C (6)-amino ethyl- 
NADH to a soluble dextran derivative yielding a cofactor 
loading of 200-300 moles NAD per gram of dextran, and was 
80% enzymatically active. Chambers (144) has bound succinyl 
NAD to amino dextran (M.W. 500,000) with 55 moles NAD per 
gram of dextran remaining, of which approximately 50% was 
enzymatically reducible with alcohol dehydrogenase. More 
recently, Larsson and Mosbach (147) have coupled the N^- 
(N-(6-aminohexyl)-acetamide) derivative of NAD to dextran 
through a long and complex synthesis. The product contained 
65 moles NAD per gram of dextran, and was about 80% active 
with alcohol dehydrogenase.
Analogous polymer-NADP complexes have met with even
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less success. In only one published example, Loweand Mosbach 
(148) have attempted to couple their (N~(6-aminohexyl)- 
acetamide) derivative of NADP to dextran. The product showed 
a reasonable NADP loading of 85 moles NADP/gm dextran, but 
a disappointing activity of only 35% compared to the native 
NADP. Furthermore, stabilities of all of these cofactor 
analogues have been unsatisfactory, and the economics are 
difficult to justify when one considers that a large percen­
tage of the costly cofactor is lost during the complex syn­
theses. As a result, there is extensive ongoing research to 
develop new methods of macromolecular cofactor production. 
Chambers (99) is currently evaluating various globular pro­
teins such as albumin for soluble supports. Preliminary 
data have indicated very high loading and enzymatic activity 
with NAD-coupled albumins. Falb (99) has taken this one 
step further by complexing NAD directly to yeast alcohol 
dehydrogenase. His preliminary unpublished results indicate 
that a loading of approximately 50 NAD molecules per enzyme 
tetramer show some activity in a cycling system using a 
number of alcohols and aldehydes.
The successes of cofactor modification must, however, 
be viewed in perspective: 1) all analyses have been con­
ducted with soluble enzymes; 2) these enzymes, usually yeast 
alcohol dehydrogenase, are typically simple, active, tough 
catalysts; and 3) only one case has demonstrated marginal 
activity of an NADP analogue, a considerably more sensitive
50
cofactor than NAD. The potential activity of an NADP ana­
logue with the immobilized MFMF oxidase is not known, much 
less its capacity for regeneration. Wykes, Dunnill, and 
Lilly, who first postulated and synthesized high molecular 
weight cofactors in 1971, have recently all but written off 
this area of research by concluding that "the cost of immo­
bilization of NAD cannot be justified unless a greater sta­
bility than that we have observed is achieved " (149) .
Multiple Loop Dialysers. An outgrowth of the double 
loop system described in the previous section would be a 
system employing three or more loops, as illustrated in 
Figure 4. The penalties of multiple cycles and multiple 
membranes include the obvious rate limitations of such a 
design, and the necessity for an increased dialysate volume. 
As a result, such a flow scheme has not been suggested in 
the literature. It has been proposed here as the result of 
what may be serious design flaws in the double loop system 
coupled with the DEAE cellulose scrubber. The consensus 
regarding the scrubber is that all efforts should 
be made to remove it from the whole blood circuit because of 
the unknown, and potentially devastating effects it may have 
in salt and protein depletion, and hemolysis.
Wishing to accrue the benefits of dealing with a rela­
tively clean dialysate in the DEAE cellulose scrubber for 
many of the same reasons enumerated for the enzyme reactor, 
a second dialysate loop was added. A comparison of Figure 4
U1
Figure 4. Multiple Loop Dialyzers. This system 
is proposed in the event the DEAE cofactor trap 
is deemed necessary. The placement of the trap 
in Figure 3 may result in serious side effects 
when in direct onctact with the blood. To pre­
clude protein agglomeration and hemolysis in the 
DEAE column, it too is placed behind a membrane.
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with Figure 3 clearly shows that the end result, conversion 
of substrate to metabolite, will occur and the toxic cofac­
tor will be entrapped before reaching the whole blood. Al­
though the absolute necessity of the scrubber has yet to be 
indicated, the foregoing is included as an exercise for this 
eventuality.
Selective Membranes 
The bulk of the foregoing has been premised on the 
known availability of various isotropic membranes in multi­
ple configurations and molecular weight range properties.
Their selectivity relies,to a great extent, on the resolution 
of differing molecular weight species. Living membranes on 
the other hand, possess high specificity not only to molecu­
lar weight, but to charge, solubility, and configuration.
Many living membranes are even capable of resolution of 
racemic mixtures (150). Significantly, they can, through 
an expension of energy known as active transport, transfer 
matter against the concentration gradient. The most widely 
known example is the selective uptake of sodium in the tu­
bule of the kidney. It is believed that all cells are capable 
of active transport to some degree. Various theories have 
been hypothesized to explain this phenomenon. It is becom­
ing apparent that several specialized systems are responsible 
for each case observed (151). Active transport has not been
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demonstrated in a totally synthetic system*, yet work is now 
underway to develop a synthetic membrane containing fragments 
of living halobacter cell wall capable of active transport 
of hydronium ion with the consumption of solar energy (152).
The topic of membrane specificity is particularly timely 
to the development of an artificial liver. An hepatocyte 
cell wall is capable of transferring various compounds for 
metabolism, and retaining others necessary for maintenance 
of the organelle. In the design of the oxidase reactor, it 
would be desirable to duplicate some of these properties; 
specificially, to allow free passage of potential substrates 
and metabolites across the dialysis membrane, while retain­
ing the compounds necessary for the net reaction (enzymes 
and cofactors). An understanding of the mechanism of trans­
fer in various membranes that may find application in such 
a system is intrinsic to their selection in a model design.
Cellulosic Membranes 
This type of membrane has found wide application in 
hemodialysis, desalinization, and other desalting operations 
which rely on the intrinsic selectivity of the polymer matrix. 
Cellulose, and cellulose acetate are highly organized poly­
mers having groups capable of hydrogen bonding to water or
other.solvents subject to hydrogen bonding, like ammonia or
* Reverse osmosis,the simultaneous concentration of one 
solution and the dilution of the other across a membrane 
due to an external pressure gradient, and electrodialysis, 
involving the consumption of electric power, are the clos­
est engineers have come so far.
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alcohols. These hydrogen bonding solvents can complex with 
the carbonyl sites in the polymer matrix, but ions and non­
hydrogen bonding substances are excluded to a greater degree 
than that observed in a non-interactive polymeric membrane 
(153) (Figure 5-A). The molecules that do enter the matrix 
as a result of hydrogen bonding then move from one bonding 
site to another and thus are transported through the poly­
mer, provided there is a driving force to cause transfer.
Such a mechanism of transfer lends itself quite readi­
ly to hemodialysis in which one wishes to retain most ionic 
salts, yet remove the hydrogen bond forming ammonia, urea, 
and some acid salts from the blood. Conversely, in an ex­
trahepatic device the volume of dialysate will be very low, 
minimizing the problem of essential ion loss. More signifi­
cantly, the lipophilic toxins of concern in hepatotoxicity 
are not well suited to tranport through a cellulosic membrane, 
Most enzyme reactors to date have utilized cellulosic hollow 
fiber membranes simply because of their wide availability.
Ion Exchange Membranes
The selectivity here derives from the net charge of 
the dialyzing species. Some are permeable to positive ions 
(cationic membranes), while others allow passage of negative 
ions (anionic membranes). This is achieved by attaching 
charged groups throughout an inert polymer matrix. In the 
case of a cation exchanger, (Figure 5-B), positive ions are 
freely dispersed in the voids between crosslinked polymer
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Figure 5-A. (153) Water Transfer in Cellulose Acetate Mem­
brane. The characteristically high water fluxes observed in 
cellulosic membranes are due largely to a hydrogen bonding 
mechanism of the water. An impurity incapable of hydrogen 
bonding tends to be excluded by the membrane.
Figure 5-B. (153) Representation of Cation-Exchange Membrane. 
As a result of the fixed negatively charged sites with the 
matrix of the neutral polymer, negatively charged ions in 
solution tend to be repelled from the interstices of the poly­
mer chains. The mobile positively charged groups, on the 
other hand, are free to move and be eluted from the membrane. 
They therefore offer no resistance to diffusion of positive 
groups in the dialysate. If positively fixed charges are 
attached to the polymer chains instead of negative fixed 
charges, the opposite type of selectivity is observed.
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chains. The fixed negative charges repel negative ions that 
try to enter the polymer matrix, hence excluding them from 
the membrane. Positive ions, on the other hand, are free 
to pass, as are the unbound positive groups that were for­
merly associated with the fixed negative species during man­
ufacture. If negative fixed charges are attached to the poly­
mer chains instead of positive fixed charges, the opposite 
type of selectivity is achieved.
In an effort to increase the stability of ion exchange 
membranes, a high degree of crosslinking has been necessary 
to retain the fixed charges and to assure high charge den­
sities within the polymer. As a result, fluxes of all but 
the smallest ions are low. A compromise must be struck 
between a loosely crosslinked structure offering little 
charge selectivity, and a tight structure with a very low 
molecular weight cutoff (153).
The reason for discussing charge selective membranes 
in this study stems from the observation that many cofactors, 
NAD and NADP included, possess a net positive charge in the 
oxidized state. Charge may possibly be used as a key to their 
selective retention within the reactor loop of Figures 3 
and 4. For example, if the reactor in Figure 3 is operated 
under cofactor limiting conditions (high enzyme concentra­
tion) , the effluent stream from the reactor will contain 
very little uncharged, reduced cofactor, and an anion ex­
change membrane may successfully retain the charged moiety.
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It then returns to the regeneration reactor, where it is 
once again reduced.
Polymeric Membrane Electrets 
Althouth cofactor charge has not been reported in the 
literature as a means of retention, the possibility is never­
theless promising. For this reason, the survey of available 
membranes was extended to allied areas of polymer technology 
in search of a more porous, charge selective membrane. It 
was discovered that properly treated polymers are capable of 
maintaining a permanent dipole electrostatic charge at room 
temperature. In theory, at least, the charged cofactor would 
be repelled from the charged surface of an electret membrane 
in much the same way as in the ion exchange membrane.
Membrane electrets are polymeric films which exhibit 
a persistent internal electrical polarization after removal 
from an external polarizing DC field. Gross (154) has shown 
that electret polarization can be described by a two charge 
theory: homocharge and heterocharge. Homocharge is due to
transfer of charge at the membrane/electrode interfact which 
results in the injection of ions into the surface of the elec­
tret. Heterocharge is due to volume polarization of the elec­
tret, i.e., dipolar alignment and space charge polarization. 
Figure 6 illustrates the probable mechanism for electret 
formation in a polymeric membrane.
Homocharge is typically the less persistent of the 
two. Results on cellulose acetate electrets indicate that
<y\
o
Figure 6. Representation of an Electret Formation. Mem­
brane electrets are formed by heating the polymer to a polar­
ization temperature and applying a high density field to the 
membrane as it cools. The formation of heterocharge deep 
within the membrane is the result of a volume polarization, or 
alignment of ion-dipoles. Homocharge is due to the injection 
of ions formed in the air gap by the high voltage applied. 
Heterocharge is stable at room temperature, whereas homocharge 
is a transient phenomenon which gradually drains off.
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homocharge decays exponentially in dry air, approaching zero 
charge in 70 days (155). This decay can be accelerated by 
immersing the charged polymer in water. All homocharge 
character is lost within one hour of water immersion (155) .
Heterocharge, conversely, appears to be a permanent 
phenomenon as long as the polymer is maintained below a cri­
tical depolarization temperature. This temperature is fre­
quently near the glass transition point for amorphous poly­
mers, presumably corresponding to a state in which the dipoles 
are free to align themselves in a more relaxed, non-aligned 
configuration (156).
The types of polymers that are conducive to being pre­
pared as electret films must fit two criteria: 1) have
adequate toughness at thicknesses of one micron and less, 
and 2) must posses polar (either mono or di-polar) groups 
capable of shifting alignment at some temperature before 
thermal decomposition occurs (156). It should be noted that 
the polymer need not be crystalline.
Polyvinylchloride (PVC) is an example of an.amorphous 
polymer which can be made into a relatively strong electret.
The repeat unit is polar with an effective dipole moment of 
3.6 X  lO”^® C'm (156). The usual form of PVC is amorphous 
because of the irregular positioning of the chloride. PVC 
is an equilibrium liquid above its glass transition tempera­
ture (about 80 C) although thermal decomposition is appreciable 
above this temperature without suitable stabilizers. Moreover,
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PVC can be manufactured in tough films which have been evalu­
ated as reverse osmosis membranes (150).
The objective in utilizing electrets (both PVC and 
cellulose acetate) in reverse osmosis systems has not been 
to exclude charged ions, but to inhibit the deposition of 
large charged colloids on the membrane surface. These con­
taminants, present in sea water, tend to redude water fluxes 
in desalinization operations by several orders of magnitude 
within a short period of time. Membrane electrets have 
markedly reduced the rate at which this gel layer is depos­
ited. Whether or not electrets can be equally effective at 
reducing NADP"*" fluxes is not known at this time. One ad­
vantage of polymer electrets has been reported in a biomedi­
cal application. Murphy (157) has reported that prosthetic 
arterial implants which possess a net negative charge on the 
surface exposed to the blood show excellent antithrombogeni- 
city. Apparently, the large, negatively charged globulins 
in the blood that trigger clotting are repelled from the 
foreign surface, greatly reducing clotting and the deposition 
of megamolecular gels on the prosthesis. The advantages of 
a non-thrombogenic, self-cleaning membrane surface are quite 
alluring to extracorporeal devices. Allowing for the neces­
sity of exposing the positively charged membrane surface to 
the reactor side containing the NADP+ in Figure 3, the negatively 
charged surface is likewise exposed to the whole blood as 
Murphy suggested —  a serendipitous discovery to say the least.
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Membrane Solubility 
Charge is not the only criterion available for produc­
ing selective synthetic membranes. Solubility was indirectly 
touched on in the cellulosic membrane discussion. Its effect 
can be greatly accentuated through proper mating of membrane 
composition and the separation desired.
Rony has modified Amicon cellulose hollow fibers by 
treatment with organic solvents to render them highly selec­
tive (158-160). In his single fiber model system (with which 
scale up has proven difficult), ethanol is converted to 
acetaldehyde with an alcohol dehydrogenase isolated within 
the modified hollow fiber and, more significantly, the co­
factor NAD is also retained. Rony describes the effect as 
the result of a stabilized liquid membrane formed in con­
junction with the existing cellulose membrane. The water- 
soluble NAD is insoluble in the organic (iso-octane) liquid 
membrane, resulting in its retention by the membrane but 
simultaneously allowing transfer of both substrate and pro­
duct, which are soluble in iso-octane and water.
Using a similar rationale, Dorson (161,162) has pre­
pared selective membranes by forcing the deposition of a 
thin lipophilic protein gel on the surface of cellulose 
films. The resultant double membrane is reportedly selective 
to polar and non-polar compounds.
The application in an extrahepatic support device of 
a membrane which derives its selectivity from solubility
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parameters warrants discussion at this point. To retain the 
cofactor (either NAD or NADP), a lipophilic barrier much like 
Rony's is called for. Now consider for a moment the typical 
substrate (toxin): it is most likely a fat soluble, middle
molecular weight molecule. Its transfer into the reactor 
system would be permitted by the same lipophilic membrane. 
Once in the reactor though, recall that the primary mode of 
detoxification is to convert this substrate to a highly polar 
molecule, an N-oxide in the case of the MFMF oxidase acting 
on a tertiary amine. The flux of this new polar metabolite 
through a lipophilic barrier will be greatly obstructed, if 
not blocked altogether. It appears, then, that no matter 
how great the potential for solubility modified membranes in 
other enzyme reactor systems, their advantages will most 
likely never be realized in an enzymatic detoxification sys­
tem. The foregoing is also applicable to a solvent extrac­
tion system in which the substrate is extracted in an organic 
layer, metabolized in an aqueous reactor, and returned to 
the patient via the donor solvent.
CONCLUSIONS
The salint feature to be gleaned from the foregoing 
potpourri is that sufficient information is currently avail­
able to launch a multifaceted attack on a problem that has 
failed to respond to the most advanced medical technology to 
date. The lethal certainty of hepatic failure allows wide
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latitudes for one wishing to attack the problem. Furthermore, 
the topic offers the engineer a rare opportunity to test rad­
ical designs normally shunned by a conservative medical com­
munity. The specific goals outlined in Chapter I are but a 
stepping stone to define more clearly the direction a project 
of this potential must take.
CHAPTER III 
MATERIALS
Purified Oxidase 
The oxidase enzyme utilized in this study has been 
isolated through a separate research effort at the University 
of Texas. Although the technique of purification has been 
dealt with in detail elsewhere (93) , a cursory review is 
included here.
The liver of mature hogs is the primary source for 
the enzyme. Although no effort has been made to increase 
the levels of this oxidase through drug treatment before 
slaughter, as has been done with the cytochrome P-450 sys­
tem (164,165), experience has shown that MFMF availability is 
affected by factors such as sex, age, and even hair color. The 
pork liver tissue is homogenized and treated ultrasonically 
to promote cell and endoplasmic reticulum rupture. The micro­
somal fraction collected after an initial centrifugation 
is re suspended in O.IM guanidine, pH 8.0, and spun at 
78,000 g for 35 minutes. The pellet is resuspended in water 
to a final protein concentration of 20 mg/ml. The oxidase 
is solubilized from its natural matrix with the detergents 
Triton X-102 and X-45 at concentrations of 5 mg each per ml.
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The detergent-protein solution is allowed to stand on ice 
for one hour, at which time 1 mg/ml protamine sulfate is 
added to precipitate surplus protein, which is removed by 
centrifugation at 78,000 g for 45 minutes. The supernatant 
fluid is immediately fractionated with an ammonium sulfate 
gradient. The fraction precipitating between 37 and 50% 
saturation is collected. This is dissolved in O.lM acetate 
buffer, pH 4-8, and maintained at that pH with sulfuric 
acid during a second fractionation with saturated ammonium 
sulfate. The fraction collected between 45 and 50% satura­
tion is dialyzed against a solution of 0.05M glycine and 
0.05M histidine, pH 6.0. The dialysate is passed through a 
DEAE cellulose column equilibrated with the glycine-histidine 
buffer and eluted with the same buffer. The effluent is 
concentrated by ultrafiltration and then transferred to a 
Sephadex G-100-120 column equilibrated with 0.03M glycine, 
pH 6.0. Elution is continued with this buffer until the 
first bright yellow fraction, the purified oxidase appears.
Allied Enzymes, Cofactors, Supports, and Organic Chemicals 
Table 1 summarizes the pertinent specifications.
Experimental Equipment and Commercial Membranes
Assay Microreactor. Figure 7 illustrates the reactor 
used for all kinetic studies with the oxidase enzyme. Fea­
tures of this design include a liquid sealed injection port 
to insure a closed reaction system, a constant temperature
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TABLE 1
Chemical Specifications and Distributors
Acetone, reagent grade, Fisher Scientific Co.
N,N-Dicycohexylacarbodiimide, 99%, Aldrich Chem­
icals
1,6-Diisocyanatohexane (DICH), Aldrich Chemicals
N,N-Dimethylaniline (DMA), Matheson Coleman and 
Bell
Dimethylsulphoxide (DMSO), tech grade, Mallinck- 
rodt
Ethyl ether, anhydrous, Mallinckrodt
Glass bead supports, AlKyl Amine Zir-clad CPG- 
1350 pourous glass beads. Corning. Distribu­
ted by Pierce Chemical Co. Nominal surface 
area: 41 m /gm; particle diameter; 177-840
microns; nominal pore diameter: 1350Â.
D-glucose-6-phosphate, monosodium salt. Sigma 
Chemical Co.
D-glucose-6-phosphate dehydrogenase, type XV, 
Sigma Chemical Co.
Glutaraldehyde, 25%, practical grade, Matheson 
Coleman and Bell Manufacturing Chemists
Heparia, monosodium salt, injection, USP, 1000 
units/ml, from beef lung, Upjohn Co.
Nicotinamide adenine dinucleotide (NAD), sodium 
salt from yeast extract, reduced and oxidized 
forms. Sigma Chemical Co.
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TABLE 1 (Continued)
Nicotinamide adenine dinucleotide phosphate 
NADP), .sodium salt, from yeast extract, re­
duced and oxidized forms. Sigma Chemical Co.
Potassium phosphate, mono and di-basic, anhydrous, 
Fisher Scientific Co.
Poly (ethylenimine), 30% solution in water,
Aldrich Chemical Co.
Polyvinylchloride, (PVC) powder from suspension 
polymerization, gift of Union Carbide.
Polyvinylchloride/Polyvinylacetate, (PVC/PVA), 
copolymer, 83% PVC, 17% PVA, powder from sus­
pension polymerization gift of Union Carbide.
Pyridine, Matheson Coleman and Bell
Succinic anhydride, Matheson Coleman and Bell
H*
Figure 7. Assay Microreactor. This reactor was 
used for all kinetics studies with the immobilized 
MFMF oxidase. The magnetic stirrer provides ade­
quate mixing to suspend the finely divided cata­
lyst, while the oxygen probe accurately measures 
the changing oxygen concentration in the closed 
system during reaction. Low catalyst requirements 
and quick turnaround time for initiation of a new 
run are two advantages of this design. The reactor 
is emptied by vacuum aspiration. Typical reaction 
mixtures are described on page 9 8.
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water jacket, coupled to a Haake constant temperature bath 
maintained at 37 ± 0.1 C, an oxygen electrode port (see be­
low) , and economical consumption of catalyst and substrate.
Sofer has shown that agitation rate is critical to reaction 
rate as well as to electrode performance(101). A magnetic stirrer 
has been added to preclude any error due to the above.
Oxygen Polarograph. The course of the oxidase reac­
tion was observed by monitoring the decreasing oxygen ten­
sion in the closed system microreactor. A Yellow Springs 
Instrument Co. Model No. 4004 Clark-type oxygen electorde 
was coupled to a Heath/Schlumberger model EU-205-11 strip 
chart recorder via a potentiometric trimming circuit built 
in this laboratory. A schematic of the entire system appears 
in Figure 8. The decision to monitor the consumption of 
oxygen as a substrate (as opposed to other substrate amines 
and cofactors) proved to be particularly convenient. The 
microreactor in conjunction with the oxygen polarograph 
allowed turnaround of less than one minute between succes­
sive runs, without complex quantitative analyses and the 
error induced by non-precision reaction termination required 
by other techniques. Reaction mixtures are described on page 98.
Heated Press. A Carver model C laboratory press cap­
able of exerting a 24,000 lb. load over a 6" x 6" area coupled 
with two Carver model 2101 independently controlled heaters 
top and bottom (room temperature to 500 ± 5°F) was used in 
the preparation of the electret membranes (see Methods).
-J
Figure 8. Schematic of Polarograph Input to Strip 
Chart Recorder via the Potentiometric Trimming Cir­
cuit. Due to the varying properties of the oxygen 
electrode with time, and membrane thickness, a 
micro-amp box is used as a coarse adjustment for 
input to the recorder. Final adjustments and 
zeroing may be made at the recorder.
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Other researchers have reported the necessity of applying 
evaporated silver electrodes to the membrane surfaces to 
eliminate air gaps and the resulting heterocharge effects 
(155,156/168). The heated press allowed the use of easily 
assembled electrode "sandwiches"; air gaps were successfully 
eliminated by applying loads in the range of 10,000 to
20,000 lbs., greatly simplifying the electret preparation 
procedure.
Membranes. Several commercially available membranes 
were evaluated, in addition to those prepared in the labora­
tory. The family of Bio-Fiber hollow fiber cellulose and 
cellulose acetate membranes, manufactured by Dow Chemical Co. 
and distributed by Bio-Rad Laboratories, Inc. have found 
numerous applications in experimental enzyme reactor systems. 
Cordis Labs, Miami, Florida, offers the only example of a 
semi-commercial biomedical application in the Cordis-Dow 
artificial kidney. Although transport properties of this 
family of hollow fiber membranes have proven difficult to 
control, the advantages of laminar tube-side flow and a 
high ratio of membrane area to jacket volume mandate their 
evaluation in a survey study. The unit chosen for testing 
is the Bio-Fiber 50 miniplant dialyzer, lot No. 342. This 
unit incorporates cellulose fibers with a nominal molecular 
weight cutoff of 5,000 in a generalized shell and tube con­
figuration. Within a shell volume of 120 ml and a fiber 
volume of 150 ml, this 10-inch dialyzer packs nominally
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15,000 cm of surface area. In comparison, the Kill dialy­
zer, using sheet membranes, is approximately ten times lar­
ger, with 30% less membrane surface area. Operation of all 
flow-type membrane cells, including the miniplant, were 
performed with Cole Parmer variable speed peristaltic pumps 
through silicon tubing.
Cellulose sheet membranes were also evaluated, due to 
the ease with which they could be modified by the electret 
process. These are simply single layers of common dialysis 
tubing, available through VWR Scientific as well as numerous 
other suppliers. The tubing, prepared of regenerated vis­
cose cellulose, is split and peeled apart to a single 
thickness, averaging between 0.5 and 0.8 mil. In 
this condition, the membrane exhibits excellent toughness 
both wet and dry, and excellent transport properties for 
water and relatively small, water soluble molecules.
Two types of ion exchange membranes were obtained from 
a commercial supplier. Both a cation transfer (no. 61-CZL- 
183) and an anion transfer (no. 103-QZL-183) were gifts 
of Ionics, Inc., Watertown, Massachusetts. These are exam­
ples of membranes currently being used in selected indus­
trial applications, most notably in electrodialysis. The 
103 series are copolymers of vinyl compounds containing 
quarternary ammonium groups and tertiary amine groups.
The 61 series consist of sulfonated copolymers of vinyl 
compounds. Both types of membrane are homogeneous films.
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cast in sheet form on a synthetic cloth backing (169,170).
Power Supply. A Harrison Model 6522 DC power supply 
with output ranges of 0 to 2000 V.D.C. and 0 to 100 mA, 
provided a high quality direct current source for generating 
high field potentials for the preparation of electret mem­
branes and for studying the behavior of charged cofactors 
within an electric field. An overload feature allows the 
power supply to be operated either within a current limiting 
or a voltage limiting mode. If the current selected is be­
yond the power capacity, the circuit automatically reverts 
to the voltage limiting mode, and vice-versa. This anomaly 
is apparent in Figure 18, but is not believed to grossly affect 
the properties of the electret being formed. The volt and 
ammeters within the power supply were deemed sufficiently 
accurate when compared to an RCA VTVM/multimeter to allow 
direct collection of voltage/current data for studies re­
quiring this information.
Ultrafiltration Membranes. Although not used directly 
in any of the flow schemes proposed, Diaflo 10 xMSO ultrafil­
tration membranes in an Amicon model 52 cell were used in 
various syntheses for protein and polymer concentration.
Test Cells. Two types of membrane test cells were 
designed and constructed of Plexiglass (Reg. trademark,
Rohm and Haas Corp., for polymethylmethacrylate). Figure .9 
illustrates exploded views of the two types. Type 1 is a 
simple, non-flow, two compartment cell, in which a small
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Figure 9-A. The Type 1 Micro Membrane Evaluation Cell.
This type of cell was used for all sheet-type membrane analy­
ses. Media of various concentrations may be placed on either 
side of the membrane, and concentration measurements taken 
at timely intervals. In addition, several of these cells 
may be placed in a shaker bath to provide intimate mixing 
on both sides of the membrane. A rubber gasket, when pro­
perly fitted, afforded a leak-proof design for multiple mem­
brane evaluations in a short period of time.
Figure 9-B. Exploded View of Tortuous Path Flow Cell. The 
type-2 cell was constructed to observe the effects of im­
pressed current on net flux behavior of charged cofactors. 
It features replaceable electrodes and membranes. A water 
seal was attained by applying a light coating of vacuum 
grease to all mating surfaces. The overall thin construc­
tion allows high current and field densities through the 
dialyzing solutions.
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sample membrane may be sandwiched between two rubber gaskets, 
Pour to five rubber bands served to hold the assmebly to­
gether. The cell can be placed in a shaker bath and agi­
tated at various speeds, or allowed to stagnate. Type 1 
cells proved so effective for quick and dirty analyses of 
membrane properties that over 15 were constructed for mass 
screenings. This generally reduced the evaluation time of 
a new membrane from several days to a matter of hours.
The Type 2 cell was constructed for two reasons ;
1) to further investigate membrane properties in a more com­
plex flow process; and 2) to study the effects of charged 
cofactors in a flow process both when exposed to an external 
field, and to an impressed current. Features of the Type 2 
cell include replaceable membranes and electrodes, and a 
reduced thickness to acentuate the effects of induced elec­
tric fields.
Spectrophotometer. An Hitachi model H-191 single 
beam spectrophotometer was used for all assays in which a 
compound exhibited sharp absorption peaks in the 200 to 
600 nm wavelength range. For the ultraviolet regions 
(<340 nm), Beckman 1307 quarts cells of 0.1 ml capacity and
1.0 cm path length were used. For visible colorimetric 
tests, Hitachi type 0120 1.0 ml, 1.0 cm path length cells
were substituted, when available.
CHAPTER IV 
METHODS
Insolubilization of Enzyme via Covalent Attachment to Pour­
ous Glass Beads
Theory
Enzyme attachment to insoluble substrates through 
various linkages is well documented in the literature (115). 
The oxidase extract of this study has been shown to be par­
ticularly well suited to immobilization by many of these 
techniques (84,100,101).
In general, the chemical methods for covalent attach­
ment draw heavily from experience gained in ligand chroma­
tography in which the matrix surface is activated, a non­
functional derivative may then be grafted onto the activated 
surface, and the organic functional group (the enzyme) is 
then attached to this "arm". The first example of a syn­
thetically produced, water insoluble, polymer bound enzyme 
derivative was described by Grubhofer and Schleith in 1953 
(171,172). In 1969, the use of glass as a support for the 
covalent attachment of enzymes was propounded by Weetal 
(173,174). Small glass particle supports offer advantages 
of high protein binding efficiency, good stability and
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inertness, as well as providing wide flexibility in the re­
actor design. Sofer (84,100,101) and Osinowo (116) have con­
ducted extensive evaluations of the oxidase in several 
reactor configurations using various insolubilizing supports, 
including glass. For small scale kinetic studies, the use 
of Corning porous glass beads (40-80 mesh) was determined 
to be the method of choice. They exhibit highly stable 
activities (over 100 times that of soluble enzyme), and may 
be conveniently stored at 4 C over buffer for indefinite 
periods. Additionally, the small particles are easily 
weighed and poured into the microassay reactor. The fore­
going is not intended to be an unequivocal commitment to 
porous glass bead catalyst supports in a hemoperfusion de­
vice. Indeed, such supports may prove quite unsatisfactory 
in regard to hemolysis and particle embolism. They simply 
offer a convenient and economical means of applying the 
enzyme for the time being.
If desired, enzyme binding efficiency may be deter­
mined by hydrolyzing the flavin groups on the oxidase, and 
observing the intensity of the resulting yellow solution at 
400 nm. It is not, however, the purpose of this study to 
investigate extensive methods of immobilizing the oxidase. 
Catalytically active glass heads were prepared by the stan­
dardized techniques that follow, and all kinetic studies 
were performed with excess catalyst.
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Bead Preparation
The following is an adaptation of a method supplied 
by Pierce Chemical Company for enzyme immobilization on 
zirconia-clad porous glass particles (175).
Twenty-five ml of a 2.5% glutaraldehyde solution was 
poured over 3 gms of Corning GAO 7920 glass beads. In addi­
tion to its role as an "arm" extension to reduce stearic 
hindrances to catalyst activity, the glutaraldehyde acts as 
a carbonyl intermediate on which to attach the enzyme via a 
Schiff base exchange. The mixture was then evacuated under 
vacuum aspiration at room temperature for 30 minutes to 
remove air bubbles and assure penetration of the glutaralde­
hyde deep within the particle pores. The vacuum was released 
and the reaction was then allowed to continue at room temp­
erature and atmospheric pressure for an additional 40 minutes. 
The glutaraldehyde solution was decanted, and the beads were 
repeatedly washed in glass distilled water until the charac­
teristic sweet aldehyde odor was no longer perceptible —  
usually at least ten washes. The activated beads are now 
ready for chemical coupling. The processed enzyme solution 
(see below) is now added to the flask containing the treated 
beads such that all particles are covered in the enzyme 
liquor. This corresponds roughly to a protein concentration 
of 30-40 mg enzyme per gram dry glass beads. Care should 
be exercised at this point to assure that the mixture remains 
chilled over an ice bath. The bead and enzyme mixture, on
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the ice slurry constantly, is once again placed under vacuum 
aspiration for two hours. The reaction may then be ' 
allowed to continue at atmospheric pressure overnight in the 
refrigerator, with occasional shaking when convenient. The 
following day the oxidase supernatant liquor is decanted and 
re-frozen. It may be used again in subsequent preparations, 
with marginal loss in activity. The catalyst is then washed 
three to five times with 30 ml aliquots of 0.025 M chilled 
K-phosphate buffer, pH 7.6, and stored in this buffer at 4 C 
until ready for use.
Enzyme Processing 
The purified oxidase is shipped on dry ice from the 
Clayton Foundation Biochemistry Labs in Austin, Texas, to the 
Norman Campus via air freight. As received, the extract has 
a protein concentration of from 5-20 mg/ml and assayed acti­
vity of from 200-1000 n moles/min-mg. An 8-10 ml sample 
is dialyzed in 0.01 M K-phosphate buffer, pH 7.6, at 0 C to 
remove glycine buffers.- 500 ml aliquots of fresh, chilled 
buffer are changed three times during the two-hour dialysis 
procedure. The dialyzed solution is ultrafiltered at 0 C to 
a final volume of 4-6 ml. This results in a final protein 
concentration of approximately 10 mg/ml.
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Preparation of a Soluble, High Molecular Weight 
Poly(ethyleneimine) NADPH Complex 
Theory
A method has been described in the literature for the 
production of a high molecular weight (~40,000) Dextran/NADP 
complex (129). In an effort to avoid duplication of this 
work and to sidestep some of the shortcomings of the pro­
cedure, an alternate method was developed in this laboratory. 
The method, a modification of a synthesis described by 
Wykes (145) involves the attachment of a soluble poly(ethyl­
eneimine) (PEI) chain to a single activated group on the NADP 
molecule.
Procedure
Eight gm of succinic anhydride were added to 40 ml of 
dimethylsulphoxide (DMSO). 224 mg of either NADP+ or NADPH
was added, and after 48 hours at room temperature, the NADP 
components were precipitated with 10 volumes of cold acetone. 
The precipitate was recovered by centrifugation and washed 
three times with acetone. The white powder was then dried 
under vacuum aspiration. The dried succinyl derivative (at 
least 200 mg) was then dissolved in 1.0 ml of water and 1.0 
ml of pyridine was added. This was followed by 50 mg of 
dicyclohexylcarbodiimide dissolved in 0.2 ml of pyridine.
The mixture was incubated at room temperature overnight.
4.0 ml of a 30% PEI solution adjusted to pH 6.0 with concen­
trated HCl were added and allowed to react for three hours
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at room temperature. The suspension was adjusted to 50 ml 
with chilled water and PEI-succinyl-NADP precipitated by the 
addition of an equal volume of chilled 1.0 M K-phosphate 
buffer, pH 6.0. Chilling of the cloudy suspension aids in 
the agglomeration of the polymer to yield a bright yellow, 
gooey pellet on centrifucation at 1000 g for five minutes.
The clear supernatant was decanted, and the precipi­
tate was re-dissolved in 10 ml of 2 M NaCl in 0.05 M acetate 
buffer, pH 5.5. 40 ml of water were then added, followed
by 50 ml of chilled 1.0 M K-phosphate buffer, pH 6.0. The 
washing procedure was repeated four times after the initial 
precipitation. The final precipitate was dissolved in acetate 
buffer as before, and dialyzed against water overnight at 
room temperature. 1.0 1 aliquots were changed every 30 min­
utes for the first two hours, and a fifth aliquot remained 
unchanged until morning. The dialyzed PEI-succinyl-NADP 
solution was concentrated to a final volume of ~10 ml in a 
high pressure ultrafilter. The ultrafiltrate is retained 
for later analysis of free NADP by testing for catalytic 
activity in the microreactor. NADP loading on the polymer 
was determined spectrophotometrically at 260 and 340 nm.
Preparation of Polymer Film Electrets
Other workers reporting on the preparation of electret 
films have in every case either evaporated electrodes or 
applied conductive paint to the film surfaces. This in it­
self is a time consuming step, and necessitates the subsequent
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removal of the conductive layer after polarization with acid 
washes, organic solvents,and the comensurate risks of mem­
brane damage. The desire to eliminate air gaps creating 
undesirable homocharge polarization is nevertheless recog­
nized. As a result, a procedure was developed in which an 
electrode sandwich could be quickly prepared, using alumi­
num foil electrodes. The sandwich was compressed at up to 
2
700 lbs/in in a heated press to eliminate air gaps. After 
polarization was complete, the sandwich could be removed 
from the press and the electrodes peeled off and discarded. 
This allowed a more rapid evaluation of a great number of 
polymer electrets. A typical procedure appears below.
An isotropic polymer film, 6.5" x 6.5" was sandwiched 
between successive layers of aluminum foil electrodes and 
dielectric sheets as shown in Figure 10. Dielectric sheets, 
also trimmed to 6.5" x 6.5" consisted of dense, high grade 
paper, 8 mils thick. Dielectrics 1 and 3 serve to insulate 
the electrodes from the press faces. Dielectric 2 was 
necessitated by arcing which occurred due to minor imperfec­
tions in the polymer film and electrodes accentuated by the 
high compressive loads. A third, uncharged aluminum sheet 
was also included to assure a smooth mating surface for both 
sides of the film. The net effect of the paper dielectric 
and foil is to reduce the effective field intensity through 
the polymer by approximately 10 times. This was more than 
offset by the capacity of the power supply and by the higher
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Figure 10. Electrode Sandwich for Electret Manufacture.
The multi-layered composite illustrated, when placed between 
the faces of the heated press under high pressure, is a sig­
nificant improvement over previous methods in which silver 
electrodes were evaporated onto the surface of the membrane. 
Dielectrics 1 and 3 insulate the charged aluminum foil elec­
trodes from the press. Dielectric 2 prevents arcing across 
the extremely thin (0.5 mil) membranes. The center, un­
charged layer of foil is strictly to assure a smooth mating 
surface for the membrane.
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potentials that can be tolerated in this design.
The sandwich of Figure 10 was than placed between the
cool faces of the press, and loads varying from 100 to 700 
2
lb/in applied. The power supply was set in the voltage 
limiting mode at 1.0 to 1.5 Kv, (greater potentials than 
1.7 Kv caused arcing through the film and dielectric sheets), 
and the electrodes connected to the respective foil tabs on 
the sandwich. At this point, it should be noted which side 
of the membrane will have the desired charge. The potential 
is allowed to accumulate to the set limit, and the indivi­
dually controlled thermostatic heaters are set at the appro­
priate polarization temperature (80 C for PVC, 60 C for 
cellulose acetate). As the temperature increases, data are 
collected at timely intervals on current, voltage, and temp­
erature. During initial stages of polarization, data should 
be taken at 15-second intervals to observe the rapid changes 
occurring. The interval can be gradually increased to sev­
eral minutes until current and temperature stabilize after 
one to two hours. At this point, all potential dipole align­
ment has probably taken place, yet the field and heating 
are usually maintained for a total of three hours to assure 
a maximum persistent charge. After this period, the heaters 
are turned off, and forced convection cooling from a large 
blower bring the press faces to room temperature within two 
hours. It is critical that the high voltage potential be 
maintained uninterrupted during this cooling period, as the
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electret will relax in a matter of seconds at high tempera­
tures. Furthermore, removal of the electret from the press 
even at modest temperatures of 45-50 C results in appreciable 
charge decay. Once the press has cooled completely, the 
sandwich is removed and the electrodes carefully peeled from 
the film. The polarity of the film may be marked directly 
on the film at this time. To assure that no destructive 
homocharge behavior will be present during membrane evalua­
tion, the film is immersed in water overnight.
Film Casting Technique
Cellulose and cellulose acetate films are widely avail­
able commercially. Demand for PVC film, however, in either 
cast, extruded, or .calendered sheets of 1 mil thickness and 
less is limited strictly to plasticized PVC. It was felt 
that a plasticized PVC electret would not allow adequate 
persistence of the charge. Plasticization reduces the rig­
idity of the polymer, in effect lowering the glass transition 
temperature, and allowing stress relaxations to proceed at 
room temperature. Due to the unavailability of non-plasticized 
PVC films, a solution casting technique was developed. A 
PVC film of good clarity, toughness, and uniformity can be 
prepared by the following technique.
PVC powder, the direct product from suspension polymer­
ization, was dissolved without further purification in tetra- 
hydrofuran (THF). THF is undesirable as a solvent for 
solution casting because of its flammability and tendency to
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form explosive peroxides when evaporated to dryness. It is 
believed nevertheless that any peroxides formed within the 
PVC matrix during casting would quickly be neutralized by 
charge transfer or even by limited crosslinking. No other 
suitable solvents for PVC were found. The THF/PVC solution 
was poured on a chilled (0°C) 7" x 7" glass plate and evenly 
distributed. The glass plate was placed within a dessicator 
containing an adjustable stand to support the plate above 
several pieces of dry ice. The dessicator was partially 
sealed, and reduced pressure was applied with a vacuum aspir­
ator. A small hole in the dessicator allowed a gentle sca­
venging of the evaporating THE. The noxious fumes were scrubbed 
out in the water venturi of the aspirator and flushed down 
the drain. Evaporation rate, critical to membrane quality, 
was controlled by temperature, and rate of scavenging of the 
solvent.
After two hours in the dessicator, the clear, tough, 
uniform PVC film was removed from the dessicator, still 
attached to the glass plate, and allowed to air dry at room 
temperature for two more hours. The isotropic membrane, 
carefully peeled from the plate is now ready for evaluation 
as is, or after conversion to an electret. While PVC films 
prepared by this process are noticeably more brittle than their 
plasticized counterparts, they do exhibit adequate toughness.
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Measurement of Membrane Permeability 
For a dialysis system composed of two closed compart­
ments with constant volumes and Vg separated by the dialy-
zer membrane, Ruiz (180) has determined that the change in 
concentration of one component is given by:
V^(dC^/dt) = -PA(Ci - Cg) (1)
where: A is the membrane area
P is the membrane permeability
C is the concentration of the moiety under study
The constant volume assumption was shown to be valid when
working with the extremely dilute solutions typical of this 
study. Since the system is closed, the mass is constant:
“ = + C2?2 <2)
Substituting (2) into (1) and integrating, we obtain:
C - C
-In ~  = PAt(V, + V_)/V.V (3)
^10 20 z J. z
where: is the initial concentration in side 1
CgQ is the initial concentration in side 2
P, the permeability may be determined from equation (3) by 
plotting -ln(C^ - - Cgg) vs. t, and multiplying
the slope of the resulting line by V^Vg/ACV^ + The
resulting permeability is most accurately described as an 
effective permeability, including bulk diffusion and film 
resistances. Its use should be limited to a quantitative 
comparison of the membranes tested in this study. Its in­
terpretation as an absolute membrane permeability in a
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mathematical model or to systems of differing geometries 
than those represented here is not recommended.
Cofactor Permeability Flux Determinations 
The cofactors NAD(H) and NADP(H) are both optically 
opaque at specific frequencies, exhibiting good linearity in 
the 0-200 uM concentration range. An ultraviolet spectro­
photometer with quartz cells was used to directly read NAD 
and NADP concentrations in all assays. The reduced nicotin­
amide moiety absorbs strongly at 340 nm, whereas the adenine 
moiety of both the oxidized and reduced nucleotides resonates 
at 260 nm. This allows resolution of both the reduced and 
oxidized moieties of either NAD or NADP in the same solution. 
The inability to distinguish between NAD and NADP spectro- 
photometrically did not pose a problem because they were 
never used jointly in the same medium.
Microcell evaluation (Figure 5-A) was performed by 
placing a standardized cofactor concentration on one side, 
glass distilled water on the other. Initial readings were 
taken, the cells agitated at room temperature in a shaker 
bath for one hour, and final concentration readings were 
taken. The error induced by taking only two data points was 
counteracted by evaluating several membranes simultaneously. 
Membrane permeability was determined by direct substitution 
into Equation (3) and an average taken.
Since in most cases the concentration of cofactor on 
the side being dialysed did not measurably change during
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the course of the one-hour runs, and the rise in cofactor 
concentration on the dialysate side is quite linear in this 
time span, total flux of cofactor as a function of concen­
tration is simple determined as follows:
Fq = CgVg/tA (4)
where: = mass flux per unit area from a concentration
^1
to a pure dialysate fluid 
Cg = concentration of dialysate at t 
Vg = constant volume of dialysate 
t = time
A = membrane area 
Hollow fiber membrane evaluation was accomplished by 
recirculating the standardized solution in the fibers against 
a recirculating dialysate fluid in the shell initially con-r 
taining a zero concentration of the compound under study.
Flow rates were held constant throughout the run. Data taken 
at 30-minute intervals was plotted according to Equation (3) 
and a graphical solution obtained for P, the permeability.
The tortuous path type-2 cell of Figure 5-B was evalu­
ated in a manner similar to the hollow fiber cell above, when 
operated as a straight dialysis unit. Recall that an added 
feature of this cell design is the ability to investigate 
the retention of charged cofactors in an impressed electric 
field or in an impressed current with electrodes in direct 
contact with the solution. In this case, data reduction was 
performed as before, yet a new variable, P*, was substituted
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for P in Equation (3). This notation is meant to emphasize 
that P* is even less a function of membrane properties than P.
Instantaneous fluxes as a function of concentration 
difference for a type-2 cell and the hollow fiber cell were 
obtained from a rearrangement of Equation (1):
?ac = - c,) . a^-'dCi/dt) (5)
where : = mass flux/unit area across a concentration dif­
ference of (Cj^  - Cg) .
DMA Permeability and Flux Determinations 
Analogous data reduction techniques as above were also 
utilized in determining DMA membrane behavior. An assay pro­
cedure for the detection of nanomolar quantities of DMA was 
developed. It is essentially a modification of a colorimetric 
method described earlier (176).
To a 0.9 ml, protein-free sample, 0.08 ml of 3 M tri­
chloroacetic acid (TCA) and 5.0 ml of 1.0 M glycine were 
added, and mixed well. Following the addition of 0.1 ml of 
1% sodium nitrate, the solution was heated in a water bath 
at 60 C for six minutes, and then cooled on an ice bath.
When kept cool, the resulting bright yellow nitroso-amine 
was stable for up to thirty minutes, during which time its 
optical density was read at 420 nm. (A A OD of 1.0 = 7.4 
yM/ml nitroso-DMA at 420 nm.) This procedure proved adequate 
for a DMA concentration range of 0.05 to 1.5 mM, Nanomolar 
quantities may be detected by reducing the volume of buffer
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initially added.
Reaction Rate Assays
MFMF oxidation rates were determined by observing the 
uptake of dissolved molecular oxygen in a closed system with 
an oxygen electrode during the course of the reaction. This 
method was first demonstrated by Poulsen, and later refined
for a continuous flow reactor system by Sofer (84). A typi­
cal aqueous reaction medium consisted of the following:
1) 0.054 M K-phosphate buffer, pH 7.4
2) 0.11 u/ml glucose-6-phosphate dehydrogenase
3) 5.0 mM glucose-6-phosphate
4) 0.5 mM N,N-dimethylanaline
5) 0.0 - 0.22 mM NADP+
6) 10 mg of catalyst (MFMF oxidase on glass beads)
For reactions without the cofactor regeneration system, items 
2 and 3 were omitted, and an equivalent amount of NADPH 
substituted in item 5. For runs in ultrafiltered serum,
0.2 ml of 0.5 M K-phosphate buffer was added as before, but 
the make-up water normally needed to fill the reactor (~1.4 
ml) was replaced with ultrafiltered serum. This corresponds 
to a solution of 75% blood/serum. For runs in whole blood 
and serum, item 1 was omitted. The reaction was initiated by 
injection of DMA following a five-minute equilibration of the 
above mixture in the reactor.
The solid catalyst was prepared in pre-weighed samples, 
generally 20 mg each. To avoid deactivation of the enzyme
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upon drying, the 20 mg sample was gingerly wicked dry with 
a tissue, and weighed moist. As a quality control check, 
several 20 mg samples prepared in this way were dried with 
acetone, and reweighed. Their dry weights averaged 8.0 ±
0.8 mg, a reasonable error when the alternative —  collection, 
drying and weighing of individual samples —  was considered. 
Furthermore, a quantitative collection of the catalyst after 
a run proved to be difficult. In some cases, a single ali­
quot of catalyst was allowed to remain in the reactor, washed 
twice ^  situ, and the next run begun with a new reaction 
medium. No detectable catalyst decay was noted within the 
range of a maximum of 3 to 4 five-minute runs with the same
catalyst charge. All reactions were carried out at 37 ±
0.01 C, and all buffered reactions at pH 7.4. The blood sys­
tems were naturally buffered at a physiological pH 7.2.
The strip chart recorder was adjusted to give a full 
scale reading corresponding to a dissolved oxygen concentra­
tion of 200 nM, an accurate and invariant figure at 37 C, 
and air saturation. The change in slope observed when an 
amount of cofactor was injected to the reaction medium was 
directly proportional to the rate of oxygen consumption,
which is itself equal to the rate of product synthesis. A
chart speed of 60 sec/in proved adequate for elucidating all 
slope changes associated with the reaction rates in this 
study.
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Blood Preparation 
Fresh whole blood was drawn from two donors on an as- 
needed basis in 60 ml aliquots in the labs of the Goddard 
Student Health Center. The blood, collected by venupuncture 
in EDTA treated evacuated vials was immediately refrigera­
ted. All reactions in blood and serum were initiated within 
two hours of collection. No clotting was noted either during 
or after the experimental period. In the whole blood studies, 
a 10 ml sample in the vial was warmed to room temperature, 
and vigorously aerated for 1-2 minutes. It was then injec­
ted directly into the reactor. A pseudo-serum was prepared 
by spinning the EDTA treated whole blood in a clinical centri­
fuge to precipitate the platelets, and the supernatant was 
used as the reaction fluid. It was not further deliberately 
re-oxygenated. Finally, serum prepared by the above method 
was ultrafiltered in a nitrogen pressurized ultrafiltration 
cell. This blood fraction took the longest to prepare (ap­
proximately one hour per reaction sample), and was provided 
the greatest chance of thermal and mechanical degradation in the 
agitated cell. It was intended to be a facsimile of a blood 
dialysate fraction.
CHAPTER V 
RESULTS
The results of this work may be divided into two broad 
categories. The first deals with the kinetic studies of the 
enzyme in various reaction media and conditions. The second 
category pertains to membrane diffusional studies of the com­
pounds of interest in this study. The two fields are neces­
sarily dependent. For example, the maximum allowable cofac­
tor concentration in the reactor depends on the expected 
permeability of the membrane to the cofactor. For the pur­
pose of this investigation, however, the membrane and kinetics 
problems have been attacked independently in an effort to 
reduce the number of variables involved with each experiment, 
and to simplify the computational techniques involved. A 
case in point is the considerable increase in complexity of 
a membrane evaluation when one must account for chemical 
reaction at the same time.
Enzyme Kinetics 
First priority was the determination of reaction rates 
to be expected in various blood components. Irrespective 
of the eventual method of administering the MFMF oxidase
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therapeutically, some degree of activity must be shown in 
blood and/or blood fractions. The success with which the 
enzyme has been immobilized and used in vitro work at 
optimum temperatures and buffered pH's has led to an almost 
cavalier attitude toward the sensitivities of the catalyst.
Many enzymes, however, show dramatic inhibition in highly 
concentrated protein solutions, and as a result, demonstra­
tion of activity in blood was of primary importance.
Figure 11 compares the activity of the immobilized MFMF 
oxidase utilizing a simultaneous G-6-P-D cofactor regeneration 
system in a pH 7.4 K-phosphate buffered solution with the 
activity observed polarographically in whole blood treated 
with EDTA. Both reactions were run at air saturated oxygen 
tensions and 37 C, with the same amount of catalyst and 
regeneration system. In contrast to the clean and sharp 
slope changes customarily observed in K-phosphate buffer, the 
whole blood studies repeatedly resulted in poor data and 
highly non-linear rate of dissolved oxygen concentration.
By this criterion, the enzyme is only capable of an activity 
roughly 1/5 of that observed in a synthetic medium based on 
initial rates, and approximately 1/3 when the rate of dissolved 
oxygen consumption is measured after 2-3 minutes, at which 
point the slope appears to be linearizing somewhat. This 
does not necessarily offer concrete support for the percent­
age of activity lost in whole blood. Hemoglobin is known to 
be an excellent buffer for blood oxygen tension. Oxygen
Figure 11. Verification of MFMF Oxidase Activity 
in Blood. The activity of the oxidase in K-phos­
phate buffer (upper curve) is compared to the ini­
tial rate observed by the oxygen polarograph (lower 
curve) and again at a point 2-3 minutes after ini­
tiation (middle curve) at which time the rate of 
changing oxygen concentration began to linearize 
somewhat. It is believed that! the oxygen buffer­
ing of the hemoglobin is masking an appreciable 
reaction rate, and is therefore deemed an unsatis­
factory method for monitoring oxidase activity in 
blood. The reaction media (see Chapter III) in 
all cases contained a soluble G-6-P-D cofactor 
regeneration system.
2.0
A -  K-phosphate buffer
0 ~  linear portion of rate 
n- initial rate
whole blood
0)
-p
c
o•H
+>
V
nt
.20 .25.05
o
a»Concentration of NADP^ (mM)
105
uptake studies indicate that whole blood is capable of an 
oxygen loading at least five times greater than that expected 
by a simple dissolution model, which has been normalized at 
200 nM oxygen tension in aqueous buffer for the purposes of 
this project. As a result, the monitoring of dissolved 
oxygen concentration may not be a valid method of determining 
enzyme rates in a system containing an oxygen buffer like 
hemoglobin. Not only is the initial oxygen equilibrium con­
stant, a complicating factor necessary for instrument calibra­
tion, but the rate at which hemoglobin unloads oxygen rela­
tive to a largely unknown MFMF oxidase rate further clouds 
the issue. This would also explain the uncharacteristic non­
linear behavior of the polarograph during initial rates.
Figure 12 strongly supports this conclusion. The re­
action rates in ultrafiltered whole blood, and unclotted 
blood from which the platelets have been removed by centri­
fugation, both illustrate excellent reaction rates comparable 
in all cases with K-phosphate buffer under the same concentra­
tions. Because the spun, unclotted supernatant presumably 
still contains all serum proteins necessary for acid/base 
buffering at an observed pH 7.2-7.4, additional K-phosphate 
buffer, pH 7.5, was not added. It is noteworthy that the 
slight decrease in reaction rate at saturated cofactor con­
centrations between the K-phosphate buffered and the serum 
protein buffered solutions can be totally accounted for by 
the marginal difference in pH (7.3 vs. 7.5). Sofer (84) has
H*
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Figure 12. MFMF Oxidase Activity in Selected Blood 
Fractions. When the hemoglobin is removed from the 
whole blood by spinning out the platelets its acti­
vity is nearly that of the K-phosphate buffered re­
action medium. Ultrafiltered serum, a facsimile of 
a blood dialysate fraction, also shows excellent 
activity with the oxidase. As before, the reaction 
media all contain the G-6-D-P regeneration system.
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shown that a difference in pH of this order of magnitude will 
result in a 7% decrease in reaction rate for the lower pH.
The buffering action of the ultrafiltered serum, on the other 
hand, was supplemented by an amount of K-phosphate buffer 
(pH 7.5) equal to that added for the totally aqueous studies. 
Since the normal buffering action of the ultrafiltered serum 
was believed to have been lost, the extra buffer is believed 
to have raised the resulting pH from approximately 7.3 to 7.5. 
The almost identical reaction rates for the totally aqueous 
and serum reaction media bear this out.
Ultrafiltered serum has been included in this study to 
represent an approximate composition of a blood dialysate 
stream for a membrane equipped reactor. In most examples of 
hemodialysis (e.g. artificial kidney), the blood dialysate is 
nowhere nearly asconcentrated as has been represented here. 
Recall, however, that we wish to deal with only a very small 
dialysate volume (200-300 ml maximum) in the ultimate appli­
cation. It is expected that the equilibration of all blood 
fractions capable of membrane transfer (with the obvious 
exception of the toxin(s) to be metabolized) will occur in a 
relatively short time, resulting in a concentrated dialysate 
comparable in composition to the ultrafiltrate of this study.
A second feature apparent in Figures 11 and 12 is the 
expected decrease in reaction rate with decreasing cofactor 
concentration. This is to be expected, yet the shape of the 
V-[s] curves plotted in Figures 11 and 12 appears to represent
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a differing type of reaction kinetics than is expected when 
the cofactor is properly treated as a cosubstrate. The sharp 
break in reaction velocity at a cofactor concentration of 
0.025 mM in all cases indicates that the NADP is behaving as 
a "true" cofactor, necessary only in catalytic concentrations, 
and is apparently not consumed at a rate proportional to re­
action rate. Recall, however, that the reaction media of 
Figures 11 and 12 contain an efficient cofactor regeneration 
system which is capable of reducing the spent NADP^ at a rate 
greater than that in which it is consumed in the oxidase re­
action. The result is an uncharacteristic behavior of the 
cofactor NADPH at low concentrations. Recent data by Ziegler 
(179) on the soluble oxidase indicate that this phenomenon is 
due to oxidase activation by the oxidized cofactor (NADP^).
In the regeneration system illustrated by the upper curve of 
Figure 13, NADP"*” is present in abundant quantities due to the 
equilibrium between the reduced and oxidized cofactor moieties 
established by the G-6-P/G-6-P-D regeneration system. In the 
non-regenerative case, represented by the lower curve of 
Figure 13, NADP^ is not present initially, and the oxidase is 
not activated by its presence. This is the first demonstra­
tion of NADP^ activation on the immobilized oxidase. Note 
that the lower curve shows a more gradual change in rate with 
changing concentration characteristic of a typical V-[s] plot, 
which indeed it is.
Cofactor regeneration, then, proves to be a great asset
H*
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Figure 13. Cofactor Regeneration as a Means of Re- 
ducing Total Required Cofactor Concentration. The 
MFMF oxidase reaction responds well to situ 
enzymatic cofactor regeneration. An equivalent 
reaction rate with regeneration (top curve) can 
maintain a saturated reaction rate with a cofac­
tor concentration one-fourth that required without 
regeneration (lower curve). The minimum concen­
tration of cofactor allowed without compromising 
reaction rate is 0.025 mM. Both reactions were 
run in K-phosphate buffer at 37 C.
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not only in terms of reducing cofactor costs, but in the abil­
ity to lower the total concentration of pyridine nucleotide in 
the reaction medium by maintaining an artificially high con­
centration of the reduced moiety, while retaining the advan­
tages of oxidase activation from the equilibrium concentration 
of NADP^. Figure 13 indicates that cofactor regeneration al­
lows as much as an 80% reduction in total pyridine nucleotide 
concentration without sacrificing a high reaction rate. This 
may prove to be a stronger argument for cofactor regeneration 
than the economic implications.
Cofactor Analogues
As originally envisioned, this project was to involve 
the design of a membrane-bound reaction utilizing the vari­
ous newly-discovered techniques of Wykes, Mosbach and Chambers 
(see Chapter I) for the synthesis of active, high molecular 
weight cofactors which would be retained by the membrane. At 
that time (later 1974) the literature was still painting a 
rosy picture for such methods, despite the disappointing 
data that had been collected to date. In an equally optimis­
tic fashion, this laboratory jumped onto the bandwagon to ex­
plore the various advantages of macromolecular cofactors.
Preliminary data indicated that a macromolecular deri­
vative of NADPH was synthesized, but at great cofactor expense, 
and with a marginal activity. A maximum reaction rate of 
approximately 10% that of the soluble native cofactor with 
the MFMF oxidase was observed, based on a cofactor loading
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determined spectrophotometrically to be 50-80 y moles NADP 
per gram of polymer. The improved activity expected with 
improving lab techniques did not materialize, but his was 
not the reason for discontinuing the project. Two more cri­
tical factors became apparent: 1) the high molecular weight
cofactor showed activity only with the soluble MFMF oxidase; 
and 2) the cofactor analogue lost all activity with either the 
soluble or insolubilized enzyme after 36 hours, irrespective 
of storage temperature.
The first point may be explained by various mechanisms.
If the enzyme lost as much as 50% of its activity upon immo­
bilization to glass beads (this is the maximum loss observed) 
and the cofactor lost 90% of its activity upon attachment to 
the polymer (as determined by studies with the soluble enzyme) , 
this results in a net activity for the system of 5% that ex­
pected under optimum conditions. This rate of reaction may 
be too low to be detected with the apparatus available. A 
second hypothesis explains the decrease in activity in a more 
mechanistic sense. Sofer (84) has shown that the reaction on 
glass bead catalyst and soluble native cofactor is diffusion 
limiting, presumable because of the location of the catalytic 
sites within the well protected bead pores. Indeed, the method 
of bead preparation stresses the activation and binding of 
the enzyme within these pores (see Chapter IV) . It is quite 
locigal, then, to assume that a cofactor molecule experiences 
the same diffusion limitations in attempting to bind at its
114
allosteric site. A macromolecular cofactor, furthermore, re­
presenting a molecular weight as much as 75 times that of its 
native counterpart, would experience greatly accentuated dif­
fusion limitations. Perhaps an enzyme immobilization tech­
nique that offered lower diffusion limitations (nylon tubing) 
would retain some net oxidase activity with the cofactor ana­
logue .
As far as the second compromising factor is concerned, 
macromolecular cofactor instability was determined by this 
laboratory to be the major, and unacceptable constraint on the 
technique. Six months later, Wykes, Dunnill and Lilly pub­
lished their sobering paper, which reached the same conclu­
sion (149) . Apparently, the problem of functional stability 
is one of pH, the reduced analogue being stable at high pH, 
and the oxidized analogue at low pH (177). Shelf life also 
posed severe limitations, regardless of storage temperature 
and medium. Freezing, or the accompanying freeze-thaw cycle, 
resulted in complete loss of activity, obviating lyophiliza- 
tion as a means of long-term storage. Vacuum dessication, 
however, seemed feasible, but the resulting pellet was very 
hard and resisted resolublization. No increase in stability 
upon drying was noted in comparison to that portion stored 
at 4 C in a buffered solution (pH 7.9).
Membrane Evaluations
Table 2 summarizes the permeability data collected on 
all the membranes studied. All membranes were tested in the
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TABLE 2-A
Membrane Permeabilities to NADP+
Membrane, thickness (mil) Avg. Permeability
(cm/min) x 10^
PVC, (1) 2.98
PVC electret, (1) 3.09
Cellulose, (0.5) 1.40
Cellulose electret (0.5) 2.84
Anion exchange, (54) 0.233
Cation exchange, (54 0.206
Bio-Fiber - 50, (0.3) 1.27
Induced field flow 
cell (0.5) 0.3 (P*>
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TABLE 2-B
Membrane Permeabilities to DMA
Membrane, thickness (mil) Avg. Permeability
(cm/min) x 10^
Bio-Fiber - 50, (0.3) 1.95 at pH 6.5
PVC electret, (1.0) 6.06 at pH 6.5
Anion exchange, (54) .295 at pH 6.5
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type-1 cell (Chapter II), with the exception of the Bio-Fiber 
50 cell, which was evaluated in its own jacketed container 
with recirculating fluids. The induced field tests were 
performed in the specialized type-2 cell. A discussion of 
the individual membranes follows.
Bio-Fiber - 50. As originally envisioned, a non­
specific, high molecular weight cutoff membrane would be the 
method of choice for isolating the whole blood from the reac­
tion loop, as discussed in Chapter II. Since cofactor flux 
was expected to be the limiting factor in the design, its 
evaluation was undertaken first, and DMA evaluated last.
There were no modifications of membrane properties ascertain­
able as a result of this sequencing.
As received from the manufacturer, the fibers have 
been stabilized with a glycerine solution which must be flushed 
from the fibers before use. Afterward, the membranes must be 
kept wet in an antiseptic formaline solution. Figure 14 
illustrates a typical run. The apparent loss of solute from 
the closed system was at first inexplicable. Leaks were 
never observed throughout the course of a run, and all 0.1 ml 
samples were returned to their respective reservoirs after 
analysis (with the exception of the nitroso-DMA samples, which 
were discarded). With repeated experimentation, however, the 
mass balance discrepancies tended to decline and the problem 
was temporarily forgotten. After several runs, it was nec­
essary to install new silicone tubing in the pump head, and
œFigure 14. Sample Data for Determination of Mem­
brane Permeabilities and Fluxes in Bio-Fiber - 50 
Flow Cell. Preliminary results with this system 
gave poor results, until it was discovered that 
NADP'*' and DMA were soluble in the silicone tubing 
used. This is an example of the superior data 
obtained after saturating the silicone tubing with 
the appropriate solute before use. The upper curve 
represents the decreasing concentration of NADP+ in 
the tube side. The lower curve illustrates the 
resultant increase in cofactor concentration in 
the shell side. Good mass conservation is noted 
after 60 minutes.
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the non-conservative mass balance once again appared. DMA, 
it was discovered, and NADP, to a lesser degree, are soluble 
in the silicone tubing, and possibly in the cellulose membrane 
and polycarbonate case. Therefore, an overnight soaking per­
iod was instituted before each run with new tubing or a new 
solute. The results in Figure 14 represent the nearly opti­
mum results from such an experiment. Figure 15 illustrates
the excellent linear correlation attainable on two typical
+ + runs on NADP and DMA. Total NADP and DMA fluxes are given
in Figures 16 and 17 respectively. Details of the data re­
duction techniques are covered in Chapter III.
Ion Exchange Membranes. It was initially observed that 
an impressed current across a cellulose membrane in a Type-1 
cell was capable of maintaining a 10-fold concentration dif­
ference of NADP^ across the membrane. This was investigated 
further in the type-2 cell, but the results were not as strik­
ing, and electrolysis was an undesirable side effect. Gold 
foil electrodes were more stable than aluminum, particularly 
at the anode, despite the fact that the "gold" leaf was mostly 
copper. In addition, electrolytic reduction and decomposi­
tion, and NADP^ attachment to the anode proved troublesome. 
Nevertheless, charge does appear to be a valid method for the 
differential separation of charged cofactors from neutral 
solutions. The method of choice at present for such a pro­
cess is through the use of ion exchange membranes. The 
"tight" characteristics of these membranes were well known
to
Figure 15. Sample Data Correlation Used in Graphi- 
cal Solution of Membrane Permeabilities. The lower 
curve is the data of Figure 14 plotted in the form 
suggested in Chapter I V  for the graphical deter­
mination of permeability.
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Figure 16. Net NADP^ Fluxes of Each Membrane Evalu­
ated. Assuming a constant membrane permeability, 
the best straight line was drawn to represent the 
cofactor flux to be expected of the patient for a 
given concentration in the reactor. Recall from 
Figure 13 that the kinetically optimum cofactor 
concentration is 0.025 M.
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Figure 17. Net DMA Fluxes of Each Membrane Evalu- 
ated. Several of the membranes initially evaluated 
in the NADP studies were eliminated due to poor 
properties. The remaining membranes that showed 
some promise were evaluated with DMA. PVC showed, 
a surprisingly high permeability to DMA. This 
is believed to be a solubility phenomenon that would 
not benefit the DMA-N-oxide product, due to its 
increased hydrophilic character. Bio-Fiber - 50 
exhibited adequate fluxes, especially when the 
large surface area is accounted for. The anion ex­
change membrane appears to be totally unacceptable 
both in regard to NADP+ and DMA fluxes.
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ahead of time, and the data confirms they are only capable
of low DMA and NADP^ fluxes. Surprisingly, within the range
of experimental error, there appears to be no substantial
+differentiation between charged moieties; NADP flux through 
the anion exchanger is comparable to that through the cation 
exchange membrane.
There is a possibility that the DMA data contains a sys­
tematic error the result of an anomaly in the construction of 
the anion-selective membrane. The fixed charges contain 
quarternary ammonium groups and tertiary amine groups. The 
possibility exists that the tertiary amines in the membrane 
are slowly leaching into the dialysate side and being identi­
fied in the nitroso-DMA test as DMA itself. It is doubtful 
that this comprises a significant error, especially when one 
considers that DMA fluxes are still quite low.
PVC and PVC-Electret Membranes. All PVC membranes were 
cast from the THF solution as described in Chapter I V .  A 
simplified casting algorithm was developed for the predictive 
determination of membrane thickness:
(0.02) (T) (A) = W 
where: T = desired membrane thickness (thousandths of an
inch)
2
A = desired membrane area (in )
W = grams of PVC which must be in casting solution 
Generally, a 5% w/v solution of PVC in THF has adequate cast­
ing properties. Membrane thicknesses less than 0.5 mil
128
ruptured easily.
The electret process was greatly simplified with the 
advent of the heated press and disposable electrode sand­
wiches. Still, this laboratory lacked the sophisticated 
equipment necessary (a vibrating probe electrometer) needed 
to measure charges on the order of 10 coulombs/cm^. In­
stead, Figure 18 is presented as evidence of the formation 
of an electret. The shape of the time/temperature and time/ 
charge curves closely resemble those obtained by others (155- 
157) in the production of verified electrets. Initially, the 
charging current decays as it normally would at room tempera­
ture. Later, the trend reverses and the current starts to 
increase in response to rising current. This is believed to 
be associated with the initial disruption of the polymer 
lattice in which free electrons are more abundant. The cur­
rent experiences a peak at approximately the same time as the 
temperature reaches its controlled value. After that, it 
gradually decays as the dipoles in the polymer align, creat­
ing a more resistive dielectric.
+Permeabilities and fluxes of DMA and NADP through PVC 
membranes appear in Figures 16 and 17, and in Table 2.
Cellulose Sheet and Cellulose Electret Membranes. Cel­
lulose, in the form of regenerated viscose cellulose dialy­
sis tubing, was re-evaluated in the Type-1 cell strictly as a 
comparison to its evaluation as an electret in much the same 
way as the PVC membranes. Unlike the PVC membranes, however.
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Figure 18. Evidence for the Formation of an 
Electret. The time/temperature and time/current 
curves superimposed in this plot contain features 
identical to those observed by others during elec­
tret preparation. This sample data from a typical 
experiment is offered as proof that an electret 
has indeed been formed.
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cellulose experienced considerable degredation in visual 
appearance and toughness during the electret-forming process, 
in addition, membrane permeabilities to all moieties 
increased. This property alone made it undesirable as a 
charge selective membrane, despite the fact that it displayed 
a similar charging curve to that for PVC in Figure 19. Per­
meabilities and fluxes for all the cellulose sheet membranes 
are given in Figure 17 and Table 2.
Agitation as a Function of NADP~^ Permeability in PVC 
Electret Membranes. Purely by accident, a series of Type-1 
cells containing PVC electrets and NADP solutions were not 
agitated in the shaker bath, as was the customary procedure 
to assure good mixing on each side of the membrane. Data 
was nevertheless collected, and it was immediately apparent 
that some selectivity had been obtained. The experiment was 
repeated with other prepared PVC electrets in other Type-1 
cells, with consistent results. The permanent charge on the 
membrane surface, however weak, was being overpowered by the 
turbulence generated on shaking. Figure 19 demonstrates a 
quantitative representation of the effect of agitation on 
membrane permeability. Although the differences are minimal 
at high degrees of agitation, at stagnation there is a marked 
44% reduction in flux of the charged NADP* across a charged 
PVC membrane with the positive face exposed to the high co­
factor concentration. This clearly suggests that a laminar 
flow cell, in which the boundary layer at the membrane is
Figure 19. PVC Electret Permeability as a Func- 
tion of Agitation. Previous data indicated no 
significant decrease in NADP"*" flux when either 
the positive or negative sides were exposed to 
the side of the cell containing the cofactor.
It appears from this data, however, that the 
slightest turbulence disturbs the static repul­
sive boundary layer near the surface of the mem­
brane. At stagnation, a significant 44% decrease 
in NADP'*' flux is observed. This suggests that 
laminar flow across the membrane face is neces­
sary to preserve this boundary layer.
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essentially undisturbed, and cross diffusion through the 
bulk liquid is comparable to a stagnate fluid, may provide 
the answer to significantly lower toxic NADP fluxes into 
the blood. Many clinical dialyzers today are capable of 
maintaining laminar flow across sheet membranes, the Kiil 
dialyzer being the most common.
Membrane overview. A comparison of the data in Fig­
ures 16, 17, and 18, and Table 2 suggests several things. 
First, the Bio-Fiber membrane is not a bad unit when one con­
siders the overall convenience and high surface area avail­
able. It does fall short, in absolute terms, of the cellu­
lose sheet, probably due to poor flow distribution in the 
shell side of the dialyzer. This could no doubt be optimized 
with baffles and increased flow rates. A flow rate of 200 
ml/min in both the tubes and the shell was selected merely 
because this is a typical flow rate through a comparably 
sized extracorporeal hemoperfusion device, the artificial 
kidney.
Secondly, the family of PVC membranes show excellent 
permeabilities to DMA, and the potential for decreasing the 
NADP* permeability (Figure 19). If one uses a criterion 
such as (DMA permeability)/ (NADP* permeability) for the se­
lection of a membrane, PVC again excells. The ratio is 12 
for the PVC electret, 1.5 for Bio-Fiber - 50, and 1.3 for 
the anion exchange membrane. This, however, may be a decep­
tive advantage. The effect is believed to be due to a solu­
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bility phenomenon, the DMA being much more soluble in PVC than 
NADP^. The effect, evidently, is not as pronounced in the 
other membranes. As was discussed earlier in Chapter I, 
specificity based on solubility is not desirable in a detoxi­
fication system because the hydrophilic product of the reac­
tion, DMA-N-oxide in this example, may have a more difficult 
time getting back across the membrane than the precursor did 
initially.
The above argument should not be construed to be an 
argument against the PVC electret. The evidence to date in­
dicates that the PVC membrane is still the preferred method, 
simply because it can be prepared as an electret. The Bio- 
Fiber - 50 system, purchased off the shelf, is not amenable 
to modification, especially by the electret process. It is 
quite possible, however, that the manufacturer can produce 
charged hollow fiber membranes in which the electret is formed 
during extrusion of the fiber by suitably charging the die. 
This, of course, would require a close alliance between the 
user and manufacturer, and currently a demand for such a pro­
duct has not been established.
As a result. Figure 20, generalized representation of 
the countercurrent fluxes of DMA and cofactor to be expected 
for a given membrane area, is premised on the use of a PVC 
electret membrane in a Kiil dialyzer. This plot, together 
with the kinetic studies of Figures 11 and 12, should prove 
to be particularly useful in sizing membrane and reactor sys­
tems given the constraint of maximum cofactor flux desired.
w
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Figure 20. A Generalized Comparison of Counter- 
Current Fluxes of Cofactor and Substrates for a 
Given Membrane Area. These curves represent a 
collation of the results in Figures 17 and 19 for 
the PVC electret membrane in an idealized laminar 
flow dialyzer. Since this membrane offers the most 
advantageous permeabilities, it has been selected 
as the current method of choice.
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CHAPTER VI 
RECOMMENDATIONS
The lethal certainty of hepatic failure allows wide 
latitudes for one wishing to attack the problem of extra- 
hepatic support in a synthetic system. As a result, the 
topic offers the engineer a rare opportunity to test radical 
designs normally shunned by the conservative medical com­
munity. This paper has attempted to focus on those wide lati­
tudes somewhat by addressing four previously unexplored 
areas: 1) oxidase activity in blood with a model compound;
2) membrane modification; 3) significantly reducing required 
cofactor concentrations; and 4) exploring macromolecular co­
factors for this system. In addition to these, several 
other avenues for potential research have emerged. For the 
time being they are best grouped into four discrete projects: 
1) animal testing; 2) computer modeling; 3) cofactor reten­
tion, phase II; and 4) isolation of various other hepatic 
extracts. Each of these projects appeals to a different 
type of researcher, underscoring the need for a unified team 
effort.
Animal testing can offer immediate results. Several
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issues have haunted this project since its inception: What
effect does a slow infusion of NADP have on a large animal? 
Can it be effectively counteracted with intramuscular injec­
tion of atropine sulphate? Once these questions have been 
answered, a device could be built overnight. The materials 
for constructing an extracorporeal shunt reactor are avail­
able in this laboratory today. At this point, the use of 
common components is advisable. A commercially available 
hollow fiber dialyzer, coupled to a nylon tube oxidase re­
actor, both known quantities, would be sufficient for animal 
testing. The knowledge that a PVC electret is capable of 
reducing cofactor flux is largely academic at this point. 
Instead, a crude, pragmatic approach to the problem is called 
for. The effectiveness of the shunt may then be evaluated 
in a series of animals representing normal, CCl^ induced 
cirrhosis, and possibly anhepatic test specimens. A more 
realistic model compound is also needed, chlorpromazine, for 
example. This study should be begun immediately because it 
will necessarily involve time consuming liaisons with other 
researchers.
The second front to be explored, a computer simulation, 
is a highly theoretical issue, yet one that totally sidesteps 
the laboratory. It will be used as a predictive tool and a 
means of fine tuning the animal testing study. It is far 
easier to modify two or three parameters in a computer pro­
gram than it is to cannulate a strung-out dog.
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Sufficient experimental data currently exists to deter­
mine all kinetic and membrane parameters for this system.
The solution will involve the straightforward solution of a 
set of simultaneous differential equations, eminently suited 
to IBM's CSMP program. The program should be capable of 
predicting concentrations of all essential moieties on each 
side of the membrane, as the reaction progresses with time.
The third project has far reaching ramifications in all 
areas of cofactor intensive enzyme research, and especially 
that concerned with the artificial liver. It has been demon­
strated that NADP+ experiences a marked electrolytic migra­
tion in solution under an impressed current. Electrolysis 
has obviated this technique for cofactor separation and/or 
retention in this study, yet the technique need not be dropped. 
Industrially, when one is faced with this problem, electrode 
area is reduced, and the anode and cathode are isolated by 
an appropriate electrolyte. Furthermore, the current re­
sulting from the two electrodes is distributed across as many 
membranes as possible. The result of such logic is commonly 
referred to as electrodialysis, a method being explored 
today for desalinization of sea water. An analogous electro- 
dialytic cell can be proposed for the retention of NADP+ (or 
any charged cofactor) within the enzyme reactor of an arti­
ficial liver. The flow scheme for a single unit is illu­
strated in Figure 21. The alternating "tight" and "loose" 
membranes would allow current flow, but the NADP+ would
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Figure 21. A Proposed Method for the Retention/Separation 
of Charged Cofactors. The alternating "tight" and "loose" 
membranes allow current.flow, but the NADP^ is continually 
attracted to a membrane through which it cannot pass. The 
uncharged substrate (DMA) and metabolite (DMA-0), on the 
other hand, will be free to diffuse in any direction, speci­
fically through the loose membranes.
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continually be attracted to a membrane through which it could 
not pass. The uncharged substrate and metabolites, on the 
other hand, would be free to diffuse in any direction, speci­
fically through the loose membrane. Numerous compromises 
must still be made for such a design. pH control will be a 
continuing problem, and electrode material will be critical. 
Ion exchange membranes could play a vital role here, where 
their poor permeability to middle molecules is immaterial.
It nevertheless appears to be a potential breakthrough in 
cofactor separation and containment.
The fourth and final area of artificial liver research 
to be investigated during this phase of development is con­
cerned with generalizing the relatively specific system 
that currently exists. The single enzyme reactor incorpor­
ating the MFMF oxidase is, despite the versatility of the 
oxidase, still representing only one detoxification pathway 
(albeit a highly significant one). The utility of an extra- 
hepatic support device incorporating several detoxification 
enzymes would offer a quantum jump in clinical significance, 
with only a marginal increase in complexity. Alas, hepatic 
oxidases, transferases, mutases, etc., are, like the MFMF 
oxidase, difficult or impossible to isolate, and quite expen­
sive. As an alternative, work has begun in this laboratory, 
and will no doubt continue, in an effort to immobilize micro- 
somes on glass beads in a manner analogous to that used for 
enzymes. The microsomes, which contain all the membrane-
144
bound enzymes of the endoplasmic reticulum, are also greatly 
benefited by insolubilization. They are easily and cheaply 
prepared from various hepatocyte sources, and respond well 
to long periods of storage. There is no doubt now that the 
extrahepatic support reactor that will see clinical use will 
employ immobilized enzymes and microsomes in its role of 
liver detoxification.
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